Access the full text.
Sign up today, get DeepDyve free for 14 days.
D. Wirtzfeld, L. Mikula, R. Gryfe, P. Ravani, E. Dicks, P. Parfrey, S. Gallinger, W. Pollett (2009)
Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces.Canadian journal of surgery. Journal canadien de chirurgie, 52 2
C. Bradley, C. Given, Zhehui Luo, Caralee Roberts, G. Copeland, B. Virnig (2007)
Medicaid, Medicare, and the Michigan Tumor Registry: A Linkage StrategyMedical Decision Making, 27
M. Šimunović, T. To, N. Baxter, A. Balshem, E. Ross, Z. Cohen, R. McLeod, P. Engstrom, E. Sigurdson (2000)
Hospital procedure volume and teaching status do not influence treatment and outcome measures of rectal cancer surgery in a large general populationJournal of Gastrointestinal Surgery, 4
E. McCarthy, R. Phillips, Zhenshao Zhong, R. Drews, Joanne Lynn (2000)
Dying with Cancer: Patients' Function, Symptoms, and Care Preferences as Death ApproachesJournal of the American Geriatrics Society, 48
S. Rulyak, M. Mandelson, T. Brentnall, C. Rutter, E. Wagner (2004)
Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer.Gastrointestinal endoscopy, 59 2
R. Wagman, B. Minsky, A. Cohen, J. Guillem, P. Paty (1998)
Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up.International journal of radiation oncology, biology, physics, 42 1
M. Pisu, L. Richardson, Young-Il Kim, H. Krontiras, Michelle Martin, M. Salas, L. Pollack (2010)
Less-than-standard treatment in rectal cancer patients: which patients are at risk?Journal of the National Medical Association, 102 3
T. Salz, M. Weinberger, J. Ayanian, N. Brewer, C. Earle, Jennifer Lafata, D. Fisher, B. Weiner, R. Sandler (2010)
Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United StatesBMC Health Services Research, 10
A. White, Chih-Chin Liu, Rui Xia, K. Burau, J. Cormier, W. Chan, Xianglin Du (2008)
Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002Cancer, 113
R. Ricciardi, P. Roberts, T. Read, P. Marcello, D. Schoetz, N. Baxter (2010)
Variability in Reconstructive Procedures Following Rectal Cancer Surgery in the United StatesDiseases of the Colon & Rectum, 53
K. Lang, Lisa Lines, David Lee, J. Korn, C. Earle, J. Menzin (2009)
Trends in healthcare utilization among older Americans with colorectal cancer: A retrospective database analysisBMC Health Services Research, 9
Ma Dong (2006)
Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for Metastatic Colorectal CancerJournal of Evidence-based Medicine
L. Påhlman (2001)
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. CommentaryThe Lancet, 358
K. Hardiman, M. Cone, B. Sheppard, D. Herzig (2009)
Disparities in the treatment of colon cancer in octogenarians.American journal of surgery, 197 5
D. Schrag (2004)
The price tag on progress--chemotherapy for colorectal cancer.The New England journal of medicine, 351 4
Nancy Baxter, D. Rothenberger, Arden Morris, K. Bullard (2005)
Adjuvant Radiation for Rectal Cancer: Do We Measure Up to the Standard of Care? An Epidemiologic Analysis of Trends Over 25 Years in the United StatesDiseases of the Colon & Rectum, 48
J. Jessup, J. Jessup, A. Stewart, F. Greene, B. Minsky (2005)
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation.JAMA, 294 21
J. Vaneenwyk, J. Campo, E. Ossiander (2002)
Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectumCancer, 95
B. Minsky (1999)
Sphincter preservation in rectal cancerInternational Journal of Clinical Oncology, 4
M. Dharma-Wardene, C. Gara, H. Au, J. Hanson, J. Hatcher (2002)
Ageism in rectal carcinoma?International Journal of Gastrointestinal Cancer, 32
C. Snyder, C. Earle, R. Herbert, B. Neville, A. Blackford, K. Frick (2008)
Trends in Follow-up and Preventive Care for Colorectal Cancer SurvivorsJournal of General Internal Medicine, 23
A. Morris, Yongliang Wei, N. Birkmeyer, J. Birkmeyer (2006)
Racial disparities in late survival after rectal cancer surgery.Journal of the American College of Surgeons, 203 6
J. Ayanian, A. Zaslavsky, C. Fuchs, E. Guadagnoli, Cynthia Creech, R. Cress, L. O'Connor, D. West, M. Allen, R. Wolf, W. Wright (2003)
Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 7
S. Dobie, J. Warren, Barbara Matthews, D. Schwartz, L. Baldwin, K. Billingsley (2008)
Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general populationCancer, 112
M. Cree, J. Tonita, D. Turner, Z. Nugent, R. Alvi, Richard Barss, Charlotte King, M. Winget (2009)
Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004.Clinical colorectal cancer, 8 3
A. Demers, S. Latosinsky, D. Turner (2008)
Survival and treatment trends of rectal cancer patients in a population with suboptimal local control.European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 34 6
R. Hilsden, H. Bryant, L. Sutherland, P. Brasher, A. Fields (2004)
A retrospective study on the use of post-operative colonoscopy following potentially curative surgery for colorectal cancer in a Canadian provinceBMC Cancer, 4
R. Luo, S. Giordano, J. Freeman, Dong Zhang, J. Goodwin (2006)
Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer.The oncologist, 11 9
D. Schrag, L. Cramer, P. Bach, C. Begg (2001)
Age and adjuvant chemotherapy use after surgery for stage III colon cancer.Journal of the National Cancer Institute, 93 11
E. Somers (1985)
International Agency for Research on Cancer.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 133 9
Emily Dunn, K. Kozak, J. Moody (2010)
External beam radiotherapy for colon cancer: patterns of care.International journal of radiation oncology, biology, physics, 76 5
MD EARLE, MD WEISER, MS VEER, MD SKIBBER, PhD WILSON, MD RAJPUT, MD WONG, MD III, MD SHIBATA, RPh ROMANUS, PhD NILAND, MD SCHRAG (2009)
Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancerJournal of Surgical Oncology, 100
T. Chan, C. Brown, Cheryl Ho, S. Gill (2010)
Primary Tumor Resection in Patients Presenting With Metastatic Colorectal Cancer: Analysis of a Provincial Population-Based CohortAmerican Journal of Clinical Oncology, 33
N. Keating, M. Landrum, E. Lamont, C. Earle, Samuel Bozeman, B. Mcneil (2010)
End‐of‐life care for older cancer patients in the Veterans Health Administration versus the private sectorCancer, 116
Jennifer Lafata, Christine Johnson, T. Ben-Menachem, R. Morlock (2001)
Sociodemographic Differences in the Receipt of Colorectal Cancer Surveillance Care Following Treatment With Curative IntentMedical Care, 39
M. Mcgory, D. Zingmond, E. Sekeris, R. Bastani, C. Ko (2006)
A Patient's Race/Ethnicity Does Not Explain the Underuse of Appropriate Adjuvant Therapy in Colorectal CancerDiseases of the Colon & Rectum, 49
J. Lipscomb, T. Gillespie (2011)
State-Level Cancer Quality Assessment and Research: Building and Sustaining the Data InfrastructureThe Cancer Journal, 17
E. Emanuel, Y. Young-Xu, N. Levinsky, G. Gazelle, O. Saynina, A. Ash (2003)
Chemotherapy Use among Medicare Beneficiaries at the End of LifeAnnals of Internal Medicine, 138
D. Romanus, M. Weiser, J. Skibber, A. Veer, J. Niland, John Wilson, A. Rajput, Y. Wong, A. Benson, S. Shibata, D. Schrag (2009)
Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis.Journal of the National Comprehensive Cancer Network : JNCCN, 7 8
Alan Cook, R. Single, L. Mccahill (2005)
Surgical Resection of Primary Tumors in Patients Who Present With Stage IV Colorectal Cancer: An Analysis of Surveillance, Epidemiology, and End Results Data, 1988 to 2000Annals of Surgical Oncology, 12
P. Loehrer (2007)
Duration of Adjuvant Chemotherapy for Colon Cancer and Survival Among the ElderlyYearbook of Oncology, 2007
J. Warren, C. Klabunde, D. Schrag, P. Bach, G. Riley (2002)
Overview of the SEER-Medicare Data: Content, Research Applications, and Generalizability to the United States Elderly PopulationMedical Care, 40
G. Ellison, J. Warren, K. Knopf, Martin Brown (2003)
Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery.Health services research, 38 6 Pt 2
S. Hendren, J. Birkmeyer, H. Yin, M. Banerjee, C. Sonnenday, A. Morris (2010)
Surgical Complications Are Associated With Omission of Chemotherapy for Stage III Colorectal CancerDiseases of the Colon & Rectum, 53
B. Edwards, A. Noone, A. Mariotto, Edgar Simard, F. Boscoe, S. Henley, A. Jemal, Hyunsoon Cho, Robert Anderson, B. Kohler, C. Eheman, E. Ward (2014)
Annual Report to the Nation on the status of cancer, 1975‐2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancerCancer, 120
(2011)
Canadian Cancer Society's Steering Committee on Cancer Statistics
A. Morris, K. Billingsley, A. Hayanga, Barbara Matthews, L. Baldwin, J. Birkmeyer (2008)
Residual treatment disparities after oncology referral for rectal cancer.Journal of the National Cancer Institute, 100 10
V. Sundararajan, V. Grann, Jacobson Js, H. Ahsan, A. Neugut (2001)
Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study.Cancer journal, 7 3
Neetu Chawla, Eboneé Butler, J. Lund, J. Warren, L. Harlan, K. Yabroff, R. Yabroff (2013)
Patterns of colorectal cancer care in Europe, Australia, and New Zealand.Journal of the National Cancer Institute. Monographs, 2013 46
Hak-Mien Quah, R. Joseph, D. Schrag, J. Shia, J. Guillem, P. Paty, L. Temple, W. Wong, M. Weiser (2007)
Young Age Influences Treatment but not Outcome of Colon CancerAnnals of Surgical Oncology, 14
H. Kirkpatrick, C. Aitelli, H. Qin, C. Becerra, W. Lichliter, A. Mccollum (2010)
Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer.Clinical colorectal cancer, 9 3
D. Schrag, Sarah Gelfand, P. Bach, J. Guillem, B. Minsky, C. Begg (2001)
Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results--Medicare.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 17
Chi Lin, M. Charlton, J. Meza, C. Enke, F. Loberiza (2010)
Temporal and Regional Variations in the Use of Preoperative Radiation Therapy for Rectal CancerAmerican Journal of Clinical Oncology, 33
G. Cooper, Jonathan Payes (2006)
Temporal trends in colorectal procedure use after colorectal cancer resection.Gastrointestinal endoscopy, 64 6
A. Neugut, M. Matasar, Xiaoyan Wang, R. McBride, J. Jacobson, W. Tsai, V. Grann, D. Hershman (2006)
Duration of adjuvant chemotherapy for colon cancer and survival among the elderly.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 15
M. Winget, S. Hossain, Y. Yasui, A. Scarfe (2010)
Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline‐recommended treatmentCancer, 116
W. Cheung, G. Pond, M. Rother, M. Krzyzanowska, C. Swallow, J. Brierley, L. Kaizer, J. Myers, L. Hajra, L. Siu (2008)
Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer.Clinical colorectal cancer, 7 3
S. Oliveria, M. Yood, U. Campbell, S. Yood, P. Stang (2004)
Treatment and Referral Patterns for Colorectal CancerMedical Care, 42
S. Latosinsky, D. Turner (2009)
Local recurrence after rectal cancer treatment in Manitoba.Canadian journal of surgery. Journal canadien de chirurgie, 52 1
G. Chang, J. Skibber, B. Feig, M. Rodriguez-Bigas (2007)
Are We Undertreating Rectal Cancer in the Elderly?: An Epidemiologic StudyAnnals of Surgery, 246
G. Cooper, T. Kou, H. Reynolds (2008)
Receipt of guideline‐recommended follow‐up in older colorectal cancer survivorsCancer, 113
A. Schroen, R. Cress (2001)
Use of Surgical Procedures and Adjuvant Therapy in Rectal Cancer Treatment: A Population-Based StudyAnnals of Surgery, 234
D. Hershman, D. Buono, J. Malin, R. McBride, W. Tsai, A. Neugut (2009)
Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.Journal of the National Cancer Institute, 101 23
R. Siegel, D. Naishadham, A. Jemal (2012)
Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 62
S. Rolnick, S. Alford, Gena Kucera, Kris Fortman, M. Yood, M. Jankowski, C. Johnson (2005)
Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer.Journal of the National Cancer Institute. Monographs, 35
V. Sundararajan, N. Mitra, J. Jacobson, V. Grann, D. Heitjan, A. Neugut (2002)
Survival Associated with 5-FluorouracilBased Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon CancerAnnals of Internal Medicine, 136
R. Ricciardi, B. Virnig, R. Madoff, D. Rothenberger, N. Baxter (2007)
The Status of Radical Proctectomy and Sphincter-Sparing Surgery in the United StatesDiseases of the Colon & Rectum, 50
F. Boscoe, D. Schrag, Kun Chen, P. Roohan, M. Schymura (2011)
Building capacity to assess cancer care in the Medicaid population in New York State.Health services research, 46 3
E. Elkin, P. Bach (2010)
Cancer's next frontier: addressing high and increasing costs.JAMA, 303 11
(2008)
, 1991 to 2002 [ published online ahead of print October 22 , 2008 ]
S. Dobie, L. Baldwin, J. Dominitz, Barbara Matthews, K. Billingsley, W. Barlow (2006)
Completion of therapy by Medicare patients with stage III colon cancer.Journal of the National Cancer Institute, 98 9
A. Neugut, A. Fleischauer, V. Sundararajan, N. Mitra, D. Heitjan, J. Jacobson, V. Grann (2002)
Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 11
Harry Spencer, George Drake (1955)
At the State LevelNASSP Bulletin, 39
J. Ferlay, Hai-rim Shin, F. Bray, D. Forman, C. Mathers, D. Parkin (2010)
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 127
P. Phang, J. Macfarlane, Robert Taylor, R. Cheifetz, N. Davis, J. Hay, G. McGregor, C. Speers, B. Sullivan, J. Pitts, A. Coldman, British Columbia. (2003)
Practice patterns and appropriateness of rectal cancer management in
K. Knopf, J. Warren, E. Feuer, M. Brown (2001)
Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries.Gastrointestinal endoscopy, 54 5
L. Baldwin, S. Dobie, K. Billingsley, Yong Cai, George Wright, J. Dominitz, W. Barlow, J. Warren, S. Taplin (2005)
Explaining black-white differences in receipt of recommended colon cancer treatment.Journal of the National Cancer Institute, 97 16
Xianglin Du, D. Lairson, C. Begley, S. Fang (2005)
Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
N. Esnaola, A. Stewart, B. Feig, J. Skibber, M. Rodriguez-Bigas (2008)
Age-, Race-, and Ethnicity-Related Differences in the Treatment of Nonmetastatic Rectal Cancer: A Patterns of Care Study From the National Cancer Data BaseAnnals of Surgical Oncology, 15
A. Potosky, L. Harlan, R. Kaplan, Karen Johnson, C. Lynch (2002)
Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 5
H. Purves, R. Pietrobon, Sheleika Hervey, U. Guller, W. Miller, K. Ludwig (2005)
Relationship Between Surgeon Caseload and Sphincter Preservation in Patients With Rectal CancerDiseases of the Colon & Rectum, 48
Xiaocheng Wu, V. Chen, P. Andrews, L. Chen, M. Hsieh, Elizabeth Fontham (2004)
Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana.The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 156 5
D. Cronin, L. Harlan, A. Potosky, L. Clegg, Jennifer Stevens, M. Mooney (2006)
Patterns of Care for Adjuvant Therapy in a Random Population-Based Sample of Patients Diagnosed with Colorectal CancerThe American Journal of Gastroenterology, 101
(2008)
v1.2, Cancer Incidence and Mortality Worldwide: IARC
G. Cooper, Žhong Yuan, A. Chak, A. Rimm (2000)
Patterns of endoscopic follow-up after surgery for nonmetastatic colorectal cancer.Gastrointestinal endoscopy, 52 1
R. Gray, R. Hills, R. Stowe, M. Clarke, R. Peto, M. Buyse, P. Piedbois (2001)
Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trialsThe Lancet, 358
Larissa Temple, L. Hsieh, W. Wong, L. Saltz, D. Schrag (2004)
Use of surgery among elderly patients with stage IV colorectal cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 17
C. Bradley, C. Given, B. Dahman, T. Fitzgerald (2008)
Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer.Archives of internal medicine, 168 5
N. Keating, M. Landrum, E. Meara, P. Ganz, E. Guadagnoli (2005)
Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?Journal of the National Cancer Institute, 97 4
L. Wudel, W. Chapman, Y. Shyr, M. Davidson, A. Jeyakumar, S. Rogers, T. Allos, S. Stain (2002)
Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival.Archives of surgery, 137 5
R. Roetzheim, Naazneen Pal, E. Gonzalez, J. Ferrante, D. Durme, J. Krischer (2000)
Effects of health insurance and race on colorectal cancer treatments and outcomes.American journal of public health, 90 11
I-lin Kuo, J. Wong, S. Roy-Chowdhury, S. Lum, J. Morgan, Kevork Kazanjian (2010)
The Use of Pelvic Radiation in Stage II Rectal Cancer: A Population-Based AnalysisThe American Surgeon, 76
Brenda Edwards, E. Ward, B. Kohler, C. Eheman, A. Zauber, Robert Anderson, A. Jemal, M. Schymura, I. Lansdorp-Vogelaar, L. Seeff, M. Ballegooijen, S. Goede, Lynn Ries (2010)
Annual report to the nation on the status of cancer, 1975‐2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future ratesCancer, 116
Jessica Diggs, Fang Xu, M. Diaz, G. Cooper, S. Koroukian (2007)
Failure to screen: predictors and burden of emergency colorectal cancer resection.The American journal of managed care, 13 3
K. Phillips, S. Liang, U. Ladabaum, J. Haas, K. Kerlikowske, D. Lieberman, R. Hiatt, M. Nagamine, Stephanie Bebber (2007)
Trends in Colonoscopy for Colorectal Cancer ScreeningMedical Care, 45
L. Shugarman, C. Bird, C. Schuster, J. Lynn (2007)
Age and gender differences in Medicare expenditures at the end of life for colorectal cancer decedents.Journal of women's health, 16 2
A. Morris, K. Billingsley, N. Baxter, L. Baldwin (2004)
Racial disparities in rectal cancer treatment: a population-based analysis.Archives of surgery, 139 2
P. Loehrer (2007)
Completion of Therapy by Medicare Patients With Stage III Colon CancerYearbook of Oncology, 2007
H. Hurwitz, L. Fehrenbacher, W. Novotny, T. Cartwright, J. Hainsworth, W. Heim, J. Berlin, A. Baron, S. Griffing, E. Holmgren, N. Ferrara, G. Fyfe, B. Rogers, R. Ross, F. Kabbinavar (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.The New England journal of medicine, 350 23
Abstract Colorectal cancer is the third most common cancer in the United States and Canada. Given the high incidence and increased survival of colorectal cancer patients, prevalence is increasing over time in both countries. Using MEDLINE, we conducted a systematic review of the literature published between 2000 and 2010 to describe patterns of colorectal cancer care. Specifically we examined data sources used to obtain treatment information and compared patterns of cancer-directed initial care, post-diagnostic surveillance care, and end-of-life care among colorectal cancer patients diagnosed in the United States and Canada. Receipt of initial treatment for colorectal cancer was associated with the anatomical position of the tumor and extent of disease at diagnosis, in accordance with consensus-based guidelines. Overall, care trends were similar between the United States and Canada; however, we observed differences with respect to data sources used to measure treatment receipt. Differences were also present between study populations within country, further limiting direct comparisons. Findings from this review will allow researchers, clinicians, and policy makers to evaluate treatment receipt by patient, clinical, or system characteristics and identify emerging trends over time. Furthermore, comparisons between health-care systems in the United States and Canada can identify disparities in care, allow the evaluation of different models of care, and highlight issues regarding the utility of existing data sources to estimate national patterns of care. Colorectal cancer is the third most common cancer (1) in the United States and Canada. In 2012, approximately 140 000 new patients were expected to be diagnosed in the United States (2) and 22 000 were expected in Canada (3). Although curable when detected early, colorectal cancer is the second leading cause of cancer death in North America, resulting in approximately 58 000 deaths per year (1). Recent improvements in the early diagnosis and treatment of colorectal cancer have led to increased survival (4–6). However, changes in treatment, especially the use of new chemotherapeutic agents, have been linked to increased costs for care (7). Given the high incidence and increased survival of colorectal cancer patients, it is beneficial for researchers, clinicians, and policy makers to characterize treatment receipt, identify populations of patients who do not receive optimal care, and quantify economic and health-care system resources needed to treat this growing population. Although similar demographically, both with sizeable immigrant populations, the United States’ multipayer system and Canada’s universal single-payer system offer differing platforms to explore how patient treatment data are collected, managed, and used to measure care patterns. Comparisons across country and health-care systems will allow the evaluation of different models of care delivery and can highlight issues regarding health-care practices and standards of care. In this systematic review of the literature, we describe patterns of care for patients diagnosed with colorectal cancer in the United States and Canada and evaluate data resources for capturing and measuring treatment patterns in both countries. Findings from this study may have implications for health-care delivery, treatment, and outcomes for patients diagnosed with colorectal cancer. Methods We used the MEDLINE database to identify articles on colorectal cancer care published in English between January 2000 and December 2010. Our search strategy combined the Medical Subject Heading (MeSH) term “Colorectal Neoplasms” with additional headings or text strings related to patterns of care, yielding 717 articles (see Appendix 1 for more details). Articles were hierarchically excluded for the following reasons: 1) the article did not report original research on receipt of colorectal cancer care; 2) the study was based on biological specimens, a nonhuman population, simulation model, or hypothetical cohort; 3) the study did not report receipt of cancer-directed initial care, postdiagnostic surveillance care, or end-of-life care; 4) the article reported results from a clinical study or controlled trial evaluating a specific treatment; 5) the study did not include information on patterns of care; 6) the study included fewer than 200 cancer patients; 7) the study did not report data for colorectal cancer care separately. After exclusions, we selected studies that were conducted in the United States or Canada. Studies conducted in Europe, Australia, and New Zealand are evaluated in a separate article (8). The reference lists of the retained articles (n = 52) were examined to identify additional studies and were evaluated by the exclusion criteria described above. An additional 21 studies were identified from reference lists and a total of 73 studies are included in this systematic review of the literature. For each article, we used a standard format to record cohort characteristics (ie, tumor site, stage, year of diagnosis or year of death in studies of end-of-life care, sample size, age distribution); health-care delivery setting and data sources used to identify patients and their health services (ie, cancer registry data, medical records, claims, surveys); and a summary of key findings on the receipt of care. Items were recorded as “Not Reported” if the information was not explicitly stated or could not be reasonably inferred from the summary statistics presented. Four reviewers participated in data abstraction. To ensure consistency between reviewers, we completed three quality control checks, where each reviewer abstracted the same three studies and compared abstracted findings. With respect to patterns of colorectal cancer care, we abstracted the proportion of patients receiving specific types of initial care, postdiagnostic surveillance care, and end-of-life care. Cancer-directed initial care consisted of surgery, radiotherapy, chemotherapy, and multicomponent care where multiple types of care were reported together and could not be abstracted separately. The summaries of postdiagnostic surveillance and end-of-life care patterns are presented in the text only, given the small number of studies. We also documented patient population and health-care provider characteristics that were associated with receipt of care and whether the associations were positive or negative. These characteristics included patient sex, race and/or ethnicity, marital status, stage of disease at diagnosis, delivery setting, and provider practice patterns (eg, cancer patient volume). We reported patterns of care across the continuum of care from initial treatment following diagnosis to postdiagnostic surveillance and, finally, end-of-life care. When appropriate, we attempted to identify when care was guideline-concordant. In each table, studies are ordered by date of publication. Results Study Characteristics Of the 73 studies included in this review (9–81), 62 were conducted in the United States and 11 were conducted in Canada (Table 1). The number of published articles on colorectal cancer care increased across the study period more rapidly in Canada, with a majority published between 2008 and 2010. Patterns of cancer-directed initial care represented the greatest number of studies for both the United States (76%) and Canada (82%), followed by studies on postdiagnostic surveillance care. Studies that reported end-of-life care were only identified in the United States (8%). With respect to cancer-directed initial care, nearly half of US studies reported on the receipt of chemotherapy (48%); in Canada, surgery, radiotherapy, and chemotherapy were assessed in similar proportions. Several studies that included a description of cancer-directed initial care fell into two or more categories used to describe “Type of care reported” or “Type of initial care reported.” Thus, these two study characteristics were not mutually exclusive. Table 1. Characteristics of studies examining the receipt of colorectal cancer in the United States and Canada Characteristic United States (n = 62) Canada (n = 11) No. % No. % Study publication year 2000–2003 18 29.0 3 27.3 2004–2007 24 38.7 1 9.1 2008–2010 20 32.3 7 63.6 Patient identification and health services data source Registry-linked medical records/claims/surveys 33 53.2 11 100.0 Registry only 11 17.7 0 0.0 Medical claims only 3 4.8 0 0.0 Other 15 24.2 0 0.0 Type of care reported* Initial care 47 75.8 9 81.8 Postdiagnostic surveillance care 11 17.7 2 18.2 End-of-life care 5 8.1 0 0.0 Type of initial care reported* Surgery 15 24.2 5 45.5 Radiation 17 27.4 4 36.4 Chemotherapy 30 48.4 5 45.5 Multicomponent 13 21.0 4 36.4 Lower bound for year of diagnosis Prior to 1990 8 12.9 4 36.4 1990–1999 41 66.1 4 36.4 2000 and later 9 14.5 3 27.3 Not reported 4 6.5 0 0.0 Tumor site reported* Colon 22 35.5 3 27.3 Rectum 19 30.6 5 45.5 Colorectal 24 38.7 4 36.4 Lower bound for age for inclusion <65 32 51.6 8 72.7 ≥65 29 46.8 0 0.0 Not reported 1 1.6 3 27.3 Number of cancer patients <500 8 12.9 5 45.5 500–999 6 9.7 1 9.1 1000–4999 14 22.6 5 45.5 5000–9999 12 19.4 0 0.0 ≥10 000 22 35.5 0 0.0 Characteristic United States (n = 62) Canada (n = 11) No. % No. % Study publication year 2000–2003 18 29.0 3 27.3 2004–2007 24 38.7 1 9.1 2008–2010 20 32.3 7 63.6 Patient identification and health services data source Registry-linked medical records/claims/surveys 33 53.2 11 100.0 Registry only 11 17.7 0 0.0 Medical claims only 3 4.8 0 0.0 Other 15 24.2 0 0.0 Type of care reported* Initial care 47 75.8 9 81.8 Postdiagnostic surveillance care 11 17.7 2 18.2 End-of-life care 5 8.1 0 0.0 Type of initial care reported* Surgery 15 24.2 5 45.5 Radiation 17 27.4 4 36.4 Chemotherapy 30 48.4 5 45.5 Multicomponent 13 21.0 4 36.4 Lower bound for year of diagnosis Prior to 1990 8 12.9 4 36.4 1990–1999 41 66.1 4 36.4 2000 and later 9 14.5 3 27.3 Not reported 4 6.5 0 0.0 Tumor site reported* Colon 22 35.5 3 27.3 Rectum 19 30.6 5 45.5 Colorectal 24 38.7 4 36.4 Lower bound for age for inclusion <65 32 51.6 8 72.7 ≥65 29 46.8 0 0.0 Not reported 1 1.6 3 27.3 Number of cancer patients <500 8 12.9 5 45.5 500–999 6 9.7 1 9.1 1000–4999 14 22.6 5 45.5 5000–9999 12 19.4 0 0.0 ≥10 000 22 35.5 0 0.0 * Not mutually exclusive. View Large Most colorectal cancer patients and health services data were identified by registry data linked to medical records, insurance claims, or physician surveys in the United States (53%); in Canada, all studies were conducted using data of this type (100%). Registry data alone accounted for patient and health services information in 18% of US studies. The remaining data sources in the United States included medical claims alone (5%) or other data sources, including special studies designed to assess treatment receipt and outcomes for cancer patients (24%). In both countries, similar numbers of studies assessed treatment for colon, rectal, and colorectal tumors, where “colorectal tumors” describe studies that assessed both colon and rectal tumor sites together and could not be abstracted separately. Several studies assessed two or more tumor sites; thus, our cohort characteristic titled “Tumor site reported” is not mutually exclusive. Several studies were represented across multiple tables or multiple times within a single table. In the United States, the majority of studies included 5000 or more patients. And in Canada, all study populations included less than 5000 patients. Health services data sources for the United States and Canada are described in Tables 2 and 3. Table 2. Characteristics of data sources used to measure patterns of colorectal cancer care in the United States* Percentage of studies Data source Data type Population coverage Patient data Health services data Date of diagnosis Stage at diagnosis Surgery Radiotherapy Chemotherapy Post-diagnosis surveillance End of life 40% SEER–Medicare Registry linked to Medicare claims ≥65 y diagnosed and treated in SEER regions √ √ √ √ √ √ √ 10% SEER Registry 17 US regions √ √ √ √ 10% State registry linked† Registry linked to supplemental data source State √ √ √ √ √ √ √ 8% State registry alone† Registry State √ √ √ √ √ √ √ 7% HCUP–NIS Hospital discharge data Nation √ 7% Special study (eg, CanCORS)† ‡ Varies Varies √ √ √ √ √ √ √ 5% Single institution† Hospital medical records Institution √ √ √ √ √ √ √ 5% Medical claims alone Medical claims Medical insurance beneficiaries √ √ √ √ √ 3% NCI Patterns of Care Registry linked to physician surveys 17 US regions √ √ √ √ √ 3% NCDB Nation √ √ √ √ √ 3% NCCN CRC outcomes database Chart review Patients treated at 8 NCI comprehensive cancer centers √ √ √ √ √ Percentage of studies Data source Data type Population coverage Patient data Health services data Date of diagnosis Stage at diagnosis Surgery Radiotherapy Chemotherapy Post-diagnosis surveillance End of life 40% SEER–Medicare Registry linked to Medicare claims ≥65 y diagnosed and treated in SEER regions √ √ √ √ √ √ √ 10% SEER Registry 17 US regions √ √ √ √ 10% State registry linked† Registry linked to supplemental data source State √ √ √ √ √ √ √ 8% State registry alone† Registry State √ √ √ √ √ √ √ 7% HCUP–NIS Hospital discharge data Nation √ 7% Special study (eg, CanCORS)† ‡ Varies Varies √ √ √ √ √ √ √ 5% Single institution† Hospital medical records Institution √ √ √ √ √ √ √ 5% Medical claims alone Medical claims Medical insurance beneficiaries √ √ √ √ √ 3% NCI Patterns of Care Registry linked to physician surveys 17 US regions √ √ √ √ √ 3% NCDB Nation √ √ √ √ √ 3% NCCN CRC outcomes database Chart review Patients treated at 8 NCI comprehensive cancer centers √ √ √ √ √ * CanCORS = Cancer Care Outcome Research and Surveillance Consortium; CRC = colorectal cancer; HCUP–NIS = Healthcare Cost and Utilization Project–Nationwide Inpatient Sample; NCCN = National Comprehensive Cancer Network; NCDB = National Cancer Data Base; NCI = National Cancer Institute; SEER = Surveillance, Epidemiology, and End Results. † Availability of health services data may vary by state, study, or institution. ‡ Availability of patient data may vary by study. View Large Table 3. Characteristics of data sources used to measure patterns of colorectal cancer care in Canada* Percentage of studies Data source Data type Population coverage Patient data Health services data Date of diagnosis Stage at diagnosis Surgery Radiotherapy Chemotherapy Postdiagnosis surveillance End of life 18% Multiple provincial registry data linked† Registry linked to chart review or EHRs Multiple provinces √ √ √ √ √ √ 18% British Columbia Cancer Agency Registry linked to medical insurance claims Province √ √ √ √ √ 18% CancerCare Manitoba Registry linked to medical insurance claims Province √ √ √ √ √ 18% Alberta Cancer Registry linked Registry linked to EHRs, hospital discharge records, or other administrative records Province √ √ √ √ 18% Single institutions† Registry linked to medical records Institution √ √ √ √ √ √ 9% Ontario Cancer Registry linked Registry linked to pathology reports Province √ √ √ Percentage of studies Data source Data type Population coverage Patient data Health services data Date of diagnosis Stage at diagnosis Surgery Radiotherapy Chemotherapy Postdiagnosis surveillance End of life 18% Multiple provincial registry data linked† Registry linked to chart review or EHRs Multiple provinces √ √ √ √ √ √ 18% British Columbia Cancer Agency Registry linked to medical insurance claims Province √ √ √ √ √ 18% CancerCare Manitoba Registry linked to medical insurance claims Province √ √ √ √ √ 18% Alberta Cancer Registry linked Registry linked to EHRs, hospital discharge records, or other administrative records Province √ √ √ √ 18% Single institutions† Registry linked to medical records Institution √ √ √ √ √ √ 9% Ontario Cancer Registry linked Registry linked to pathology reports Province √ √ √ * EHR = electronic health record. † Availability of health services data may vary by province or institution. View Large Cancer-Directed Initial Care—Surgery, Radiotherapy, Chemotherapy, and Multicomponent Care The receipt of surgical care for colorectal cancer was reported in 16 US studies and 4 Canadian studies (Table 4). Health services data were obtained from a variety of sources, including state or provincial registries with or without linkage to medical claims or patient records, hospital discharge data (eg, the Healthcare Cost and Utilization Project [HCUP]), or the National Cancer Data Base. Study cohorts were drawn from single institutions and national-, state-, or provincial-based populations. Most studies reported receipt of surgery near or above 80% in both the United States and Canada. Surgery as the sole treatment modality decreased across time, giving way to treatment plans that included neoadjuvant or adjuvant therapy (13,31). Older and uninsured patients had the highest proportions of emergency resections (23), and several studies reported an increasing trend over time for the proportion of rectal cancer patients receiving sphincter-sparing surgery. Surgery receipt varied by anatomical location of the tumor, race, sex, and age. Table 4. Patterns of care for the initial receipt of surgery for colorectal cancer in the United States and Canada* Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Hardiman, 2009 (9) United States Any 1998–2004 10 433 ≥80, 30 Oregon; patients and health services data identified through the Oregon State Cancer Registry Overall, patients aged ≥80 were as likely to receive surgery as were younger patients; older patients were less likely to have surgery if they had regional, distant, or unknown disease Rectal Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims Overall, 90% of patients received surgery; surgery receipt increased with increased stage (stage I: 85%, stage II: 93%, stage III: 95%) Ricciardi, 2010 (11) United States NR NR 19 912 NR Multiple states; patients and health services data identified through the HCUP–NIS 50% of discharges had a sphincter-sparing procedure; county-level data showed geographical variability in the receipt of sphincter-sparing techniques; one-fourth of counties treated ≥60% of patients with nonrestorative surgical techniques Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 22–88 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 47% of patients received anterior resection, 51% received APR, 2% received Hartmann’s procedure; 53% of patients received a permanent stoma Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 74% of patients received surgery; surgery alone was the most common treatment modality across the study period, though surgery alone decreased from 60% to 40% between 1985 and 1999 Esnaola, 2008 (14) United States I–III 2003–2005 35 695 ≥65, 51 Multiple states; patients identified from the NCDB; health services data obtained by medical record abstraction Older patients (≥75) were less likely to receive surgery compared with younger patients (<55); older patients were more likely to receive local excision instead of definitive, segmental resection; compared with white patients, black patients were less likely to receive surgery Chang, 2007 (15) United States I–III 1991–2002 21 390 Median 68 Multiple states; patients and health services data identified from SEER 11% of patients did not receive cancer-directed surgery, 15% of patients received local excision, 44% of patients received LAR, 26% of patients received APR, and 4% of patients received multivisceral resection Ricciardi, 2007 (16) United States NR NR 117 773 Mean 66 Multiple states; patients and health services data identified through the HCUP–NIS Among patients who received surgery, 40% received sphincter-sparing procedures; the proportion of sphincter-sparing surgery increased from approximately 30% in 1988 to approximately 50% in 2003 Morris, 2006 (17) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Segmental resection was performed on 56% of black patients and 62% of white patients (P = .005); APR was more common among blacks (30%) than whites (28%); the proportion of transanal resection was similar in both groups Purves, 2005 (18) United States NR NR 477 ≥65, 25 Multiple states; patients and health services data identified through the HCUP–NIS 46% of patients had an APR and 54% had a sphincter-sparing procedure; patients treated by surgeons who had higher caseloads were more likely to undergo a sphincter-sparing procedure Morris, 2004 (19) United States Any 1988–1999 52 864 ≥35, 100 Multiple states; patients and health services data identified from SEER 96% of white patients and 94% of black patients received surgery; among these, 63% and 57% of white and black patients, respectively, received a sphincter-sparing procedure; overall, black patients were less likely to receive any type of surgery Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients identified through the British Columbia Cancer Agency; health services data from chart review and physician surveys The majority of rectal cancers were resected: 51% by anterior resection, 33% by APR, 5% by Hartmann’s procedure, and 1% by proctocolectomy Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California; patients and health services data identified from the Cancer Surveillance Program (Sacramento) More than 93% of patients received surgery; 22% of patients with middle rectum tumors and 55% of those with lower rectum tumors received APR; LAR was associated with female sex, tumor location, and treatment at a major teaching hospital Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40 British Columbia; patients and health services data identified through the British Columbia Cancer Agency 70% of patients underwent resection of the primary tumor; those who did not receive resection were more likely to have rectal tumors Diggs, 2007 (23) United States Any 2002 26 269 ≥65, 79 Multiple states; patients and health services data identified through the HCUP–NIS Patients ≥85 y were most likely to undergo emergency resection; for patients aged <65 y, emergency resection receipt was highest among those who were uninsured Cook, 2005 (24) United States IV 1988–2000 17 658 ≥50, 91 Multiple states; patients and health services data identified from SEER 66% of patients received resection; women, blacks, rectal cancer patients, and patients with leftsided colon cancers were less likely to have surgery Temple, 2004 (25) United States IV 1990–1991 9011 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 72% of patients received cancer-directed surgery; age ≥75 y, rectal lesions, leftsided colon tumors, and lower SES were associated with decreased likelihood of undergoing surgery Wudel, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases at a university medical center and a city hospital in the Nashville area There was no difference in curative resection by race or hospital; at the university hospital, 74% of black patients and 81% of white patients received curative surgery; at the city hospital, 73% of black patients and 78% of white patients received curative surgery Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 80% of patients received surgery; a higher proportion of female, married, Medicare HMO, regional stage, and colon cancer patients received surgery Simunovic, 2000 (28) Canada NR 1990 1072 ≥20, 100 Ontario; patients identified through the registry and health services data from pathology report review 31% of patients received APRs; 32% of all procedures were performed in high-volume hospitals Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Hardiman, 2009 (9) United States Any 1998–2004 10 433 ≥80, 30 Oregon; patients and health services data identified through the Oregon State Cancer Registry Overall, patients aged ≥80 were as likely to receive surgery as were younger patients; older patients were less likely to have surgery if they had regional, distant, or unknown disease Rectal Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims Overall, 90% of patients received surgery; surgery receipt increased with increased stage (stage I: 85%, stage II: 93%, stage III: 95%) Ricciardi, 2010 (11) United States NR NR 19 912 NR Multiple states; patients and health services data identified through the HCUP–NIS 50% of discharges had a sphincter-sparing procedure; county-level data showed geographical variability in the receipt of sphincter-sparing techniques; one-fourth of counties treated ≥60% of patients with nonrestorative surgical techniques Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 22–88 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 47% of patients received anterior resection, 51% received APR, 2% received Hartmann’s procedure; 53% of patients received a permanent stoma Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 74% of patients received surgery; surgery alone was the most common treatment modality across the study period, though surgery alone decreased from 60% to 40% between 1985 and 1999 Esnaola, 2008 (14) United States I–III 2003–2005 35 695 ≥65, 51 Multiple states; patients identified from the NCDB; health services data obtained by medical record abstraction Older patients (≥75) were less likely to receive surgery compared with younger patients (<55); older patients were more likely to receive local excision instead of definitive, segmental resection; compared with white patients, black patients were less likely to receive surgery Chang, 2007 (15) United States I–III 1991–2002 21 390 Median 68 Multiple states; patients and health services data identified from SEER 11% of patients did not receive cancer-directed surgery, 15% of patients received local excision, 44% of patients received LAR, 26% of patients received APR, and 4% of patients received multivisceral resection Ricciardi, 2007 (16) United States NR NR 117 773 Mean 66 Multiple states; patients and health services data identified through the HCUP–NIS Among patients who received surgery, 40% received sphincter-sparing procedures; the proportion of sphincter-sparing surgery increased from approximately 30% in 1988 to approximately 50% in 2003 Morris, 2006 (17) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Segmental resection was performed on 56% of black patients and 62% of white patients (P = .005); APR was more common among blacks (30%) than whites (28%); the proportion of transanal resection was similar in both groups Purves, 2005 (18) United States NR NR 477 ≥65, 25 Multiple states; patients and health services data identified through the HCUP–NIS 46% of patients had an APR and 54% had a sphincter-sparing procedure; patients treated by surgeons who had higher caseloads were more likely to undergo a sphincter-sparing procedure Morris, 2004 (19) United States Any 1988–1999 52 864 ≥35, 100 Multiple states; patients and health services data identified from SEER 96% of white patients and 94% of black patients received surgery; among these, 63% and 57% of white and black patients, respectively, received a sphincter-sparing procedure; overall, black patients were less likely to receive any type of surgery Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients identified through the British Columbia Cancer Agency; health services data from chart review and physician surveys The majority of rectal cancers were resected: 51% by anterior resection, 33% by APR, 5% by Hartmann’s procedure, and 1% by proctocolectomy Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California; patients and health services data identified from the Cancer Surveillance Program (Sacramento) More than 93% of patients received surgery; 22% of patients with middle rectum tumors and 55% of those with lower rectum tumors received APR; LAR was associated with female sex, tumor location, and treatment at a major teaching hospital Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40 British Columbia; patients and health services data identified through the British Columbia Cancer Agency 70% of patients underwent resection of the primary tumor; those who did not receive resection were more likely to have rectal tumors Diggs, 2007 (23) United States Any 2002 26 269 ≥65, 79 Multiple states; patients and health services data identified through the HCUP–NIS Patients ≥85 y were most likely to undergo emergency resection; for patients aged <65 y, emergency resection receipt was highest among those who were uninsured Cook, 2005 (24) United States IV 1988–2000 17 658 ≥50, 91 Multiple states; patients and health services data identified from SEER 66% of patients received resection; women, blacks, rectal cancer patients, and patients with leftsided colon cancers were less likely to have surgery Temple, 2004 (25) United States IV 1990–1991 9011 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 72% of patients received cancer-directed surgery; age ≥75 y, rectal lesions, leftsided colon tumors, and lower SES were associated with decreased likelihood of undergoing surgery Wudel, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases at a university medical center and a city hospital in the Nashville area There was no difference in curative resection by race or hospital; at the university hospital, 74% of black patients and 81% of white patients received curative surgery; at the city hospital, 73% of black patients and 78% of white patients received curative surgery Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 80% of patients received surgery; a higher proportion of female, married, Medicare HMO, regional stage, and colon cancer patients received surgery Simunovic, 2000 (28) Canada NR 1990 1072 ≥20, 100 Ontario; patients identified through the registry and health services data from pathology report review 31% of patients received APRs; 32% of all procedures were performed in high-volume hospitals * APR = abdominoperineal resection; HCUP–NIS = Healthcare Cost and Utilization Project–Nationwide Inpatient Sample; HMO = health maintenance organization; LAR = lower anterior resection; NCDB = National Cancer Data Base; NR = not reported; RT = radiotherapy; SEER = Surveillance, Epidemiology, and End Results; SES = socioeconomic status. † For studies where age distributions were not explicitly stated, we include measures of mean, median, or range as reflected in the original study’s presentation. ‡ Median shown at university medical center, city hospital, respectively. View Large Twenty-one studies reported patterns of care for the receipt of radiotherapy in the United States and Canada (Table 5). Surveillance, Epidemiology, and End Results (SEER) registries alone or linked to Medicare claims were used to identify radiotherapy receipt for a plurality of US studies. Similarly, all studies of radiotherapy use in Canada obtained data from provincially based cancer registries augmented by treatment data from medical records (ie, CancerCare Manitoba and the British Columbia Cancer Agency). Patients with stage II–III, local, or regional rectal cancer had the greatest representation within studies of radiotherapy; for this subset, rates of radiotherapy use increased from approximately 15% in the mid-1970s to 50% or greater in the first decade of the 21st century. This upward trend was evident in both Canada and the United States (13,35) and is in accordance with findings from randomized controlled trials that have demonstrated survival benefits from the use of radiotherapy in the treatment of early-stage rectal cancer (82). Table 5. Patterns of care for the initial receipt of radiotherapy for colorectal cancer in the United States and Canada* Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Dunn, 2010 (29) United States I–III 1988–2005 187 004 ≥60, 81 Multiple states; patients and health services data identified from SEER Less than 10% of nonmetastatic patients received RT; patients diagnosed in 1988 were 2.5 times more likely to receive RT than those diagnosed in 2005 Rectal Kuo, 2010 (30) United States II 1994–2003 329 Range 28–93 California; patients and health services data identified through the registry’s Desert Sierra Cancer Surveillance Program 54% of patients received pelvic RT; among these, 71% received RT postoperatively Lin, 2010 (31) United States II–III 1998–2005 8978 ≥18, 100 Multiple states; patients and health services data identified from SEER 31% of patients received preoperative RT, 37% received postoperative RT, and 31% received no RT Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 15% of patients received neoadjuvant RT, 25% received adjuvant RT; over time, a higher proportion of patients received preoperative RT compared with postoperative RT Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 22–88 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 47% of patients received adjuvant RT; receipt of RT increased by stage; 1% of patients received neoadjuvant RT Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 93% of stage III patients aged ≤80 y and who underwent curative surgery received RT within 6 mo of diagnosis Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) Receipt of RT increased 32% to 40% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 55% of all patients received RT; 48% of stage II and 62% of stage III patients received RT Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 57% of blacks and 65% of whites consulted with a radiation oncologist; among these, 74% of blacks and 83% of whites received RT after consultation Chang, 2007 (15) United States I–III 1991–2002 21 390 Median 68 Multiple states; patients and health services data identified through SEER 47% of patients received adjuvant RT; increasing age was associated with decreased receipt of RT Morris, 2006 (34) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Among patients with stage II to IV disease, black patients were less likely to receive RT compared with white patients (25% vs 34%) Baxter, 2005 (35) United States Local regional 1976–2005 45 627 ≥18, 100 Multiple states; patients and health services data identified from SEER Overall, 32% of patients received RT; receipt increased 15% to 42% from 1976 to 2000; younger age, male sex, and regional spread was associated with RT use Morris, 2004 (19) United States Any 1988–1999 52 864 ≥35, 100 Multiple states; patients and health services data identified from SEER 47% of white patients and 44% of black patients received any RT; 7% of white patients and 7% of black patients received neoadjuvant RT Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients were identified through the British Columbia Cancer Agency; chart review and physician surveys were used to obtain health services data 60% of stage II and stage III patients received RT; of these, 89% received postoperative radiation and 11% received neoadjuvant radiation Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 48% of patients received RT following surgery; 11% of patients received RT only for adjuvant therapy Schrag, 2001 (37) United States II–III 1992–1996 1411 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 57% of patients received RT; increasing age was associated with decreased likelihood of RT receipt Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California; patients and health services data identified from the Cancer Surveillance Program (Sacramento) 14% of stage I, 53% of stage II, 63% of stage III, and 30% of stage IV patients received RT Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40% British Columbia; patients and health services data identified through the British Columbia Cancer Agency 63% of resected and 58% of nonresected rectal cancer patients received RT Ayanian, 2003 (38) United States II–III 1996–1997 1956 ≥18, 100% California; patients were identified from the registry; health services data obtained from physician surveys or hospital records Based on registry data, 58% of patients received RT; this proportion increased to 64% with additional data obtained from physician surveys or hospital records; black and older patients were less likely to receive RT Wudell, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases at a university medical center and a city hospital in the Nashville area There was no significant difference in RT receipt by race or hospital; at the university hospital, 7% of black patients and 10% of white patients received RT; at the city hospital, 7% of black patients and 6% of white patients received RT Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data were obtained from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 26% of patients received RT; a higher proportion of male, married, lower income, smoking, Medicaid, distant stage, and rectal cancer patients received surgery Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Dunn, 2010 (29) United States I–III 1988–2005 187 004 ≥60, 81 Multiple states; patients and health services data identified from SEER Less than 10% of nonmetastatic patients received RT; patients diagnosed in 1988 were 2.5 times more likely to receive RT than those diagnosed in 2005 Rectal Kuo, 2010 (30) United States II 1994–2003 329 Range 28–93 California; patients and health services data identified through the registry’s Desert Sierra Cancer Surveillance Program 54% of patients received pelvic RT; among these, 71% received RT postoperatively Lin, 2010 (31) United States II–III 1998–2005 8978 ≥18, 100 Multiple states; patients and health services data identified from SEER 31% of patients received preoperative RT, 37% received postoperative RT, and 31% received no RT Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 15% of patients received neoadjuvant RT, 25% received adjuvant RT; over time, a higher proportion of patients received preoperative RT compared with postoperative RT Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 22–88 Manitoba; patients and health services data obtained through CancerCare Manitoba, which houses registry and treatment data 47% of patients received adjuvant RT; receipt of RT increased by stage; 1% of patients received neoadjuvant RT Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 93% of stage III patients aged ≤80 y and who underwent curative surgery received RT within 6 mo of diagnosis Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) Receipt of RT increased 32% to 40% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 55% of all patients received RT; 48% of stage II and 62% of stage III patients received RT Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 57% of blacks and 65% of whites consulted with a radiation oncologist; among these, 74% of blacks and 83% of whites received RT after consultation Chang, 2007 (15) United States I–III 1991–2002 21 390 Median 68 Multiple states; patients and health services data identified through SEER 47% of patients received adjuvant RT; increasing age was associated with decreased receipt of RT Morris, 2006 (34) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Among patients with stage II to IV disease, black patients were less likely to receive RT compared with white patients (25% vs 34%) Baxter, 2005 (35) United States Local regional 1976–2005 45 627 ≥18, 100 Multiple states; patients and health services data identified from SEER Overall, 32% of patients received RT; receipt increased 15% to 42% from 1976 to 2000; younger age, male sex, and regional spread was associated with RT use Morris, 2004 (19) United States Any 1988–1999 52 864 ≥35, 100 Multiple states; patients and health services data identified from SEER 47% of white patients and 44% of black patients received any RT; 7% of white patients and 7% of black patients received neoadjuvant RT Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients were identified through the British Columbia Cancer Agency; chart review and physician surveys were used to obtain health services data 60% of stage II and stage III patients received RT; of these, 89% received postoperative radiation and 11% received neoadjuvant radiation Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 48% of patients received RT following surgery; 11% of patients received RT only for adjuvant therapy Schrag, 2001 (37) United States II–III 1992–1996 1411 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 57% of patients received RT; increasing age was associated with decreased likelihood of RT receipt Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California; patients and health services data identified from the Cancer Surveillance Program (Sacramento) 14% of stage I, 53% of stage II, 63% of stage III, and 30% of stage IV patients received RT Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40% British Columbia; patients and health services data identified through the British Columbia Cancer Agency 63% of resected and 58% of nonresected rectal cancer patients received RT Ayanian, 2003 (38) United States II–III 1996–1997 1956 ≥18, 100% California; patients were identified from the registry; health services data obtained from physician surveys or hospital records Based on registry data, 58% of patients received RT; this proportion increased to 64% with additional data obtained from physician surveys or hospital records; black and older patients were less likely to receive RT Wudell, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases at a university medical center and a city hospital in the Nashville area There was no significant difference in RT receipt by race or hospital; at the university hospital, 7% of black patients and 10% of white patients received RT; at the city hospital, 7% of black patients and 6% of white patients received RT Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data were obtained from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 26% of patients received RT; a higher proportion of male, married, lower income, smoking, Medicaid, distant stage, and rectal cancer patients received surgery * NCCN = National Comprehensive Cancer Network; NR = not reported; RT = radiotherapy; SEER = Surveillance, Epidemiology, and End Results. † For studies where age distributions were not explicitly stated, we include measures of mean, median, or range as reflected in the original study’s presentation. ‡ Median shown at university medical center, city hospital, respectively. View Large Patterns of care for the receipt of chemotherapy were reported in 29 US studies and 5 Canadian studies (Table 6). SEER–Medicare or state registry data linked to Medicare claims provided treatment information for a majority of studies in the United States. The remaining US studies obtained data through hospital registries, a health maintenance organization (HMO) insurance network, or special studies of cancer patients (eg, the National Comprehensive Cancer Network’s (NCCN) Colon/Rectum Cancer Outcomes Database). As in other studies of initial care for Canada, chemotherapy treatment data were obtained from provincial registries linked to supplemental data sources. Several methods and definitions were used to assess chemotherapy receipt, even within studies, yielding a wide range of estimates. In the United States, lower use of chemotherapy was observed among patients with Medicaid coverage and those with comorbidities. And although black and white patients received consultation with an oncologist in similar proportions, white patients were significantly more likely to receive chemotherapy compared with black patients (34,50). Table 6. Patterns of care for the initial receipt of chemotherapy for colorectal cancer in the United States and Canada* Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Kirkpatrick, 2010 (39) United States II 1995–2003 287 ≥65, 69 Texas; patients identified through the Baylor University Medical Center tumor registry; health services data from chart review Among patients receiving resection, 56% were referred to a medical oncologist, 28% received adjuvant chemotherapy; receipt of chemotherapy was associated with age at diagnosis, comorbidity score, tumor grade, and stage Winget, 2010 (40) Canada III 1999–2000 772 ≥70, 56 Alberta; patients identified from the registry; health services data obtained from hospital discharge data and EMRs Among patients who received surgery, 80% received an oncologist consultation within 6 mo of diagnosis; 63% of patients with an oncologist consultation received chemotherapy Earle, 2009 (41) United States II 2005–2008 258 ≥65, 46 Multiple states; patients and health services data identified from the NCCN Colon/Rectum Cancer Outcomes Database 46% of patients received chemotherapy; 77% of patients who initiated chemotherapy completed at least 4 mo of therapy; an oxaliplatin-containing regimen was used for 67% of patients Hardiman, 2009 (9) United States Any 1998–2004 10 433 ≥80, 30 Oregon; patients and health services data identified through the Oregon State Cancer Registry Patients aged ≥80 y received chemotherapy less often than younger patients; older patients who did receive chemotherapy were less likely to receive multiple agents Hershman, 2009 (42) United States NR 1991–2002 13 422 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Study cohort was limited to patients who received chemotherapy; 17% received erythropoiesis-stimulating agents Wirtzfeld, 2009 (43) Canada I–III 1999–2000 419 NR Newfoundland and Labrador, Ontario; patient and health services data from the Newfoundland and Labrador Familial Colorectal Cancer Registry, the Ontario Familial Colorectal Cancer Registry, medical record review, and questionnaire 0% of stage I, 37% of stage II, and 92% of stage III colon cancer patients received chemotherapy Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 90% of stage III patients aged ≤80 y received chemotherapy within 4 mo of diagnosis Bradley, 2008 (44) United States I–IV 1997–2000 4675 ≥66, 100 Michigan; patients identified from the registry; health services data identified from Medicare and Medicaid insurance claims Oncologist consultations were received by 81% of Medicaid beneficiaries and 85% of Medicare-only beneficiaries; 23% of Medicaid beneficiaries and 34% of Medicare-only beneficiaries initiated chemotherapy; of these, 48% of Medicaid beneficiaries and 62% of Medicare-only beneficiaries completed chemotherapy regimens Quah, 2007 (45) United States I–III 1990–2001 1327 Median 70 New York; patients and health services data identified from the MSKCC Colorectal Service Database and chart review Younger patients (≤40 y) were more likely to receive chemotherapy compared with older patients: 39% vs 14% of stage II patients, 87% vs 80% of stage III patients Dobie, 2006 (46) United States III 1992–1996 5778 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Researchers classified receipt of chemotherapy using both liberal (1 claim-day in a month) and conservative (3 claim-days in a month) definitions; by the conservative definition, 16% initiated and 38% completed chemotherapy; by the liberal definition, 12% initiated and 42% completed chemotherapy Luo, 2006 (47) United States III 1992–1999 8978 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 78% of patients saw an oncologist within 6 mo of diagnosis; 59% of patients received chemotherapy within 6 mo of diagnosis; consultation with a medical oncologist, younger age, white race, being married, and later year of diagnosis were associated with receipt of chemotherapy McGory, 2006 (48) United States III 1994–2001 13 231 Mean 69 California; patients identified from the registry; health services data from California Patient Discharge Database 48% of patients received chemotherapy Neugut, 2006 (49) United States III 1995–1999 3733 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare More than 30% of patients were treated with chemotherapy for 1 to 4 mo; chemotherapy treatment for 5–7 mo was associated with younger age, more recent year of diagnosis, being married, having a tumor of well/moderately differentiated grade, and having no comorbidities Baldwin, 2005 (50) United States III 1992–1996 5294 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare There was no difference in the proportions of white and black patients who received consultation with an oncologist (79% and 79%, respectively, P = 0.922); however, a significant difference in treatment receipt was observed where 70% of whites and 60% of blacks received chemotherapy (P < 0.001) Jessup, 2005 (51) United States III 1990–2002 85 934 ≥60, 79 Multiple states; patients and health services data from the National Cancer Data Base Use of adjuvant chemotherapy increased from 39% in 1990 to 64% in 2002; these percentages include the use of both chemotherapy and biological response-modifiers (primarily 5-FU, levamisole, and BCG vaccine) Keating, 2005 (52) United States III 1993–1999 48 027 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Increases in market share of managed care by county was not associated with receipt of adjuvant chemotherapy (P = .94) Wu, 2004 (53) United States III 2001 303 ≥65, 63 Louisiana; patients identified from the registry; health services data from medical records of patients treated in CoC and non-CoC hospitals Receipt of chemotherapy based on race/sex was as follows: 65% white/male, 66% white/female, 72% black/male, 66% black/female; 75% of patients treated at CoC hospital and 54% at non-CoC hospital Sundararajan, 2002 (54) United States III–IV 1992–1996 4768 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 4% of patients received chemotherapy that did not include 5-FU, whereas 52% received 5-FU-based therapy; younger age was strongly associated with receiving 5-FU treatment Schrag, 2001 (55) United States III 1991–1996 6262 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 55% of all patients received chemotherapy; older age was associated with decreased likelihood of receipt of chemotherapy Sundararajan, 2001 (56) United States III 1992–1996 4998 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Approximately 50% of patients received 5-FU during the study period; use of 5-FU increased by 10% between 1992 and 1996 Rectal Kuo, 2010 (30) United States II 1994–2003 329 Range 28–93 California; patients and health services data identified through the registry’s Desert Sierra Cancer Surveillance Program 45% of patients received chemotherapy; among these, 11% of patients received chemotherapy only in addition to surgery Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 11% of patients received neoadjuvant chemotherapy; 37% received adjuvant chemotherapy Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 81% of stage II/III patients aged ≤80 y received chemotherapy within 4 mo of diagnosis Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) Receipt of chemotherapy increased 13% to 37% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 52% of all patients received chemotherapy; 42% of stage II and 63% of stage III patients received chemotherapy Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 73% of blacks and 75% of whites consulted with a medical oncologist; following consultation, 54% of blacks and 70% of whites received chemotherapy Morris, 2006 (17) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Among patients with stage II to IV disease, black patients were less likely to receive chemotherapy compared with white patients (27% vs 40%) Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients were identified through the British Columbia Cancer Agency; chart review and physician surveys were used to obtain health services data 60% of stage II and stage III patients received adjuvant chemotherapy Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 51% of patients received adjuvant chemotherapy with 5-FU-containing regimens; 14% of patients received a 5-FU regimen only in addition to surgery Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 Sacramento, California; patients and health services data identified from the Cancer Surveillance Program 11% of stage I patients, 54% of stage II patients, 70% of stage III patients, and 55% of stage IV patients received chemotherapy Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40 British Columbia; patients and health services data identified through the British Columbia Cancer Agency 61% of resected patients and 58% nonresected patients received chemotherapy Hendren, 2010 (57) United States III 1998–2005 17 108 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare; patients receiving RT were excluded 66% of patients received adjuvant chemotherapy; surgical complications were associated with nonreceipt of chemotherapy Oliveria, 2004 (58) United States I–IV 1997–1999 217 Mean 72 Massachusetts; patient and health services data obtained from HMO administrative data and medical record review 48% of stage I patients, 60% of stage II patients, 87% of stage III patients, and 67% of stage IV patients received consultation with an oncologist; among those who received consultation with an oncologist, 14% of stage I patients, 44% of stage II patients, 67% of stage III patients, and 61% of stage IV patients received chemotherapy Ayanian, 2003 (38) United States II–III 1996–1997 1956 ≥18, 100 California; patients were identified from the registry; health services data obtained from physician surveys or hospital records Based on registry data, 59% of patients received chemotherapy; this proportion increased to 67% with additional data obtained from physician surveys or hospital records; older and unmarried patients were less likely to receive chemotherapy Wudel, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases, a university medical center, and a city hospital in the Nashville area There was no difference in chemotherapy receipt by race or hospital; at the university hospital, 16% of black patients and 21% of white patients received chemotherapy; at the city hospital, 16% of black patients and 25% of white patients received chemotherapy Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data were obtained from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 21% of patients received chemotherapy; a higher proportion of married, smoking, uninsured, distant stage, and rectal cancer patients received surgery Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Kirkpatrick, 2010 (39) United States II 1995–2003 287 ≥65, 69 Texas; patients identified through the Baylor University Medical Center tumor registry; health services data from chart review Among patients receiving resection, 56% were referred to a medical oncologist, 28% received adjuvant chemotherapy; receipt of chemotherapy was associated with age at diagnosis, comorbidity score, tumor grade, and stage Winget, 2010 (40) Canada III 1999–2000 772 ≥70, 56 Alberta; patients identified from the registry; health services data obtained from hospital discharge data and EMRs Among patients who received surgery, 80% received an oncologist consultation within 6 mo of diagnosis; 63% of patients with an oncologist consultation received chemotherapy Earle, 2009 (41) United States II 2005–2008 258 ≥65, 46 Multiple states; patients and health services data identified from the NCCN Colon/Rectum Cancer Outcomes Database 46% of patients received chemotherapy; 77% of patients who initiated chemotherapy completed at least 4 mo of therapy; an oxaliplatin-containing regimen was used for 67% of patients Hardiman, 2009 (9) United States Any 1998–2004 10 433 ≥80, 30 Oregon; patients and health services data identified through the Oregon State Cancer Registry Patients aged ≥80 y received chemotherapy less often than younger patients; older patients who did receive chemotherapy were less likely to receive multiple agents Hershman, 2009 (42) United States NR 1991–2002 13 422 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Study cohort was limited to patients who received chemotherapy; 17% received erythropoiesis-stimulating agents Wirtzfeld, 2009 (43) Canada I–III 1999–2000 419 NR Newfoundland and Labrador, Ontario; patient and health services data from the Newfoundland and Labrador Familial Colorectal Cancer Registry, the Ontario Familial Colorectal Cancer Registry, medical record review, and questionnaire 0% of stage I, 37% of stage II, and 92% of stage III colon cancer patients received chemotherapy Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 90% of stage III patients aged ≤80 y received chemotherapy within 4 mo of diagnosis Bradley, 2008 (44) United States I–IV 1997–2000 4675 ≥66, 100 Michigan; patients identified from the registry; health services data identified from Medicare and Medicaid insurance claims Oncologist consultations were received by 81% of Medicaid beneficiaries and 85% of Medicare-only beneficiaries; 23% of Medicaid beneficiaries and 34% of Medicare-only beneficiaries initiated chemotherapy; of these, 48% of Medicaid beneficiaries and 62% of Medicare-only beneficiaries completed chemotherapy regimens Quah, 2007 (45) United States I–III 1990–2001 1327 Median 70 New York; patients and health services data identified from the MSKCC Colorectal Service Database and chart review Younger patients (≤40 y) were more likely to receive chemotherapy compared with older patients: 39% vs 14% of stage II patients, 87% vs 80% of stage III patients Dobie, 2006 (46) United States III 1992–1996 5778 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Researchers classified receipt of chemotherapy using both liberal (1 claim-day in a month) and conservative (3 claim-days in a month) definitions; by the conservative definition, 16% initiated and 38% completed chemotherapy; by the liberal definition, 12% initiated and 42% completed chemotherapy Luo, 2006 (47) United States III 1992–1999 8978 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 78% of patients saw an oncologist within 6 mo of diagnosis; 59% of patients received chemotherapy within 6 mo of diagnosis; consultation with a medical oncologist, younger age, white race, being married, and later year of diagnosis were associated with receipt of chemotherapy McGory, 2006 (48) United States III 1994–2001 13 231 Mean 69 California; patients identified from the registry; health services data from California Patient Discharge Database 48% of patients received chemotherapy Neugut, 2006 (49) United States III 1995–1999 3733 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare More than 30% of patients were treated with chemotherapy for 1 to 4 mo; chemotherapy treatment for 5–7 mo was associated with younger age, more recent year of diagnosis, being married, having a tumor of well/moderately differentiated grade, and having no comorbidities Baldwin, 2005 (50) United States III 1992–1996 5294 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare There was no difference in the proportions of white and black patients who received consultation with an oncologist (79% and 79%, respectively, P = 0.922); however, a significant difference in treatment receipt was observed where 70% of whites and 60% of blacks received chemotherapy (P < 0.001) Jessup, 2005 (51) United States III 1990–2002 85 934 ≥60, 79 Multiple states; patients and health services data from the National Cancer Data Base Use of adjuvant chemotherapy increased from 39% in 1990 to 64% in 2002; these percentages include the use of both chemotherapy and biological response-modifiers (primarily 5-FU, levamisole, and BCG vaccine) Keating, 2005 (52) United States III 1993–1999 48 027 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Increases in market share of managed care by county was not associated with receipt of adjuvant chemotherapy (P = .94) Wu, 2004 (53) United States III 2001 303 ≥65, 63 Louisiana; patients identified from the registry; health services data from medical records of patients treated in CoC and non-CoC hospitals Receipt of chemotherapy based on race/sex was as follows: 65% white/male, 66% white/female, 72% black/male, 66% black/female; 75% of patients treated at CoC hospital and 54% at non-CoC hospital Sundararajan, 2002 (54) United States III–IV 1992–1996 4768 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 4% of patients received chemotherapy that did not include 5-FU, whereas 52% received 5-FU-based therapy; younger age was strongly associated with receiving 5-FU treatment Schrag, 2001 (55) United States III 1991–1996 6262 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 55% of all patients received chemotherapy; older age was associated with decreased likelihood of receipt of chemotherapy Sundararajan, 2001 (56) United States III 1992–1996 4998 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Approximately 50% of patients received 5-FU during the study period; use of 5-FU increased by 10% between 1992 and 1996 Rectal Kuo, 2010 (30) United States II 1994–2003 329 Range 28–93 California; patients and health services data identified through the registry’s Desert Sierra Cancer Surveillance Program 45% of patients received chemotherapy; among these, 11% of patients received chemotherapy only in addition to surgery Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 11% of patients received neoadjuvant chemotherapy; 37% received adjuvant chemotherapy Romanus, 2009 (32) United States I–IV 2005–2008 2042 ≥65, 50 Multiple states; patients and health services data obtained from the NCCN Outcomes Database Project 81% of stage II/III patients aged ≤80 y received chemotherapy within 4 mo of diagnosis Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) Receipt of chemotherapy increased 13% to 37% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 52% of all patients received chemotherapy; 42% of stage II and 63% of stage III patients received chemotherapy Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 73% of blacks and 75% of whites consulted with a medical oncologist; following consultation, 54% of blacks and 70% of whites received chemotherapy Morris, 2006 (17) United States I–IV 1992–1999 10 940 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Among patients with stage II to IV disease, black patients were less likely to receive chemotherapy compared with white patients (27% vs 40%) Phang, 2003 (20) Canada 0–IV 1996 481 Median 70 British Columbia; patients were identified through the British Columbia Cancer Agency; chart review and physician surveys were used to obtain health services data 60% of stage II and stage III patients received adjuvant chemotherapy Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 51% of patients received adjuvant chemotherapy with 5-FU-containing regimens; 14% of patients received a 5-FU regimen only in addition to surgery Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 Sacramento, California; patients and health services data identified from the Cancer Surveillance Program 11% of stage I patients, 54% of stage II patients, 70% of stage III patients, and 55% of stage IV patients received chemotherapy Colorectal Chan, 2010 (22) Canada IV 2000–2002 411 ≥70, 40 British Columbia; patients and health services data identified through the British Columbia Cancer Agency 61% of resected patients and 58% nonresected patients received chemotherapy Hendren, 2010 (57) United States III 1998–2005 17 108 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare; patients receiving RT were excluded 66% of patients received adjuvant chemotherapy; surgical complications were associated with nonreceipt of chemotherapy Oliveria, 2004 (58) United States I–IV 1997–1999 217 Mean 72 Massachusetts; patient and health services data obtained from HMO administrative data and medical record review 48% of stage I patients, 60% of stage II patients, 87% of stage III patients, and 67% of stage IV patients received consultation with an oncologist; among those who received consultation with an oncologist, 14% of stage I patients, 44% of stage II patients, 67% of stage III patients, and 61% of stage IV patients received chemotherapy Ayanian, 2003 (38) United States II–III 1996–1997 1956 ≥18, 100 California; patients were identified from the registry; health services data obtained from physician surveys or hospital records Based on registry data, 59% of patients received chemotherapy; this proportion increased to 67% with additional data obtained from physician surveys or hospital records; older and unmarried patients were less likely to receive chemotherapy Wudel, 2002 (26) United States I–IV 1990–1999 668 Median 69, 74‡ Tennessee; data were collected through cancer registry databases, a university medical center, and a city hospital in the Nashville area There was no difference in chemotherapy receipt by race or hospital; at the university hospital, 16% of black patients and 21% of white patients received chemotherapy; at the city hospital, 16% of black patients and 25% of white patients received chemotherapy Roetzheim, 2000 (27) United States Any 1994 9551 Mean 72 Florida; patients identified through the Florida Cancer Data System; health services data were obtained from statewide hospital and ambulatory surgical centers, freestanding RT centers, and diagnostic imaging centers Overall, 21% of patients received chemotherapy; a higher proportion of married, smoking, uninsured, distant stage, and rectal cancer patients received surgery * 5-FU = 5-Fluorouracil; CoC = Commission on Cancer; BCG = Bacillus Calmette–Guérin; EMR = electronic medical record; HMO = health maintenance organization; MSKCC = Memorial Sloan-Kettering Cancer Center; NCCN = National Comprehensive Cancer Network; NR = not reported; RT = radiotherapy; SEER = Surveillance, Epidemiology, and End Results. † For studies where age distributions were not explicitly stated, we include measures of mean, median, or range as reflected in the original study’s presentation. ‡ Median shown at university medical center, city hospital, respectively. View Large Seventeen studies reported receipt of multicomponent care for the treatment of colorectal cancer in the United States or Canada (Table 7). Among studies that referenced published guidelines for the receipt of adjuvant therapy, adherence ranged between approximately 50% and 80%. Patients and health services data were identified from various sources, including SEER Patterns of Care, the National Cancer Data Base, and provincial registries in Canada. Table 7. Patterns of care for the initial receipt of multicomponent therapy for colorectal cancer in the United States and Canada* Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Cree, 2009 (59) Canada III 2004 3280 ≥65, 70 Alberta, Manitoba, and Saskatchewan; patients identified from registry; health services data from medical record review and/or through cancer registry 53% of stage III patients received standard care (surgery + chemotherapy and/or RT), as per the NIH Consensus Conference statement Cronin, 2006 (60) United States II–III 2000 475 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys 61% of stage III patients received guideline therapy (surgery + 5-FU + leucovorin/levamisole); notably, due to a lack of consensus on guideline treatment for stage II disease, these patients were not included in survival or regression analyses VanEenwyk, 2002 (61) United States III 1996–1997 632 ≥65, 71 Washington; patients identified from the registry linked to hospital discharge data 38% of patients did not receive adjuvant therapy (any chemotherapy or RT) in their treatment plan; older age, not having private health insurance, and living in a lower income area was associated with not having an adjuvant therapy treatment plan Rectal Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 17% of patients received chemoradiation Cree, 2009 (59) Canada II–III 2004 3280 ≥65, 70 Alberta, Manitoba, and Saskatchewan; patients identified from registry; health services data from medical record review and/or through cancer registry 51% of stage II–III rectal cancer patients received standard care (surgery + chemotherapy and/or RT), as per the NIH Consensus Conference statement Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 27–96 Manitoba; patients identified from the registry; health services data identified from medical records Chemotherapy was administered concomitantly for more than 80% of patients who received RT Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) The combination of major surgery and perioperative chemoradiation increased from 1% to 25% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 45% of patients received both chemotherapy and RT; 38% of stage II and 54% of stage III patients received both chemotherapy and RT Esnaola, 2008 (14) United States I–III 2003–2005 35 695 ≥65, 51 Multiple states; patients identified from the NCDB; health services data obtained by medical record abstraction Increasing age was associated with lower use of chemoradiation Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Following consultation with an oncologist, 77% of whites and 61% of blacks received both chemotherapy and RT Cronin, 2006 (60) United States II–III 2000 352 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys 55% of stage II and 53% of stage III rectal cancer patients received guideline therapy (surgery + 5-FU + RT) McGory, 2006 (48) United States III 1994–2001 13 231 Mean 69 California; patients identified from the registry; health services data from California Patient Discharge Database 52% of stage I and 62% of stage II patients received chemoradiation Keating, 2005 (52) United States III 1993–1999 48 027 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Increases in market share of managed care by county were associated with receipt of adjuvant chemoradiation for patients with stage II or stage III cancer; rates peaked in areas with a market share of managed care between 1% and 10% (P = 0.001). Dharma- Wardene, 2002 (62) Canada NR 1985–1999 2925 Median 69 Manitoba; patients identified from registry and health services data obtained from CancerCare Manitoba The combination of major surgery and perioperative chemoradiation increased from 1% to 25% between 1985 and 1999 Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 37% of patients received surgery with RT and 5-FU chemotherapy VanEenwyk, 2002 (61) United States III 1996–1997 632 ≥65, 71 Washington; patients identified from the registry linked to hospital discharge data 27% of patients did not receive adjuvant therapy (any chemotherapy or RT); older age and later stage were associated with not having an adjuvant therapy treatment plan Schrag, 2001 (37) United States II–III 1992–1996 1411 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 42% of patients received chemoradiation; increasing age reduced likelihood of treatment receipt Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California (Sacramento); patients and health services data identified from the Cancer Surveillance Program Evaluated by NIH Consensus Conference recommendations, 44% of stage II patients and 60% of stage III patients received recommended therapy (surgery + RT + chemotherapy) Colorectal White, 2008 (63) United States I–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 77% of white patients and 74% of black patients received standard therapy according to NCI Physician Data Query guidelines Potosky, 2002 (64) United States II–III 1987–1995 4706 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys Standard therapy = 5-FU + levamisole/ leucovorin for stage III colon patients, 5-FU with or without RT for stage II/III rectal patients; 78% of patients <55 y received standard therapy; 58% of whites, compared with 47% of blacks, received standard therapy Site First author, year (ref.) Country Stage Diagnosis year Sample size Age, y, %† Health delivery setting and data sources Findings Colon Cree, 2009 (59) Canada III 2004 3280 ≥65, 70 Alberta, Manitoba, and Saskatchewan; patients identified from registry; health services data from medical record review and/or through cancer registry 53% of stage III patients received standard care (surgery + chemotherapy and/or RT), as per the NIH Consensus Conference statement Cronin, 2006 (60) United States II–III 2000 475 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys 61% of stage III patients received guideline therapy (surgery + 5-FU + leucovorin/levamisole); notably, due to a lack of consensus on guideline treatment for stage II disease, these patients were not included in survival or regression analyses VanEenwyk, 2002 (61) United States III 1996–1997 632 ≥65, 71 Washington; patients identified from the registry linked to hospital discharge data 38% of patients did not receive adjuvant therapy (any chemotherapy or RT) in their treatment plan; older age, not having private health insurance, and living in a lower income area was associated with not having an adjuvant therapy treatment plan Rectal Pisu, 2010 (10) United States I–III 1999–2003 675 ≥65, 100 Alabama; patients identified through registry; health services data from Medicare claims 17% of patients received chemoradiation Cree, 2009 (59) Canada II–III 2004 3280 ≥65, 70 Alberta, Manitoba, and Saskatchewan; patients identified from registry; health services data from medical record review and/or through cancer registry 51% of stage II–III rectal cancer patients received standard care (surgery + chemotherapy and/or RT), as per the NIH Consensus Conference statement Latosinsky, 2009 (12) Canada I–III 1984–1997 333 Range 27–96 Manitoba; patients identified from the registry; health services data identified from medical records Chemotherapy was administered concomitantly for more than 80% of patients who received RT Demers, 2008 (13) Canada NR 1985–1999 2925 ≥60, 79 Manitoba; patients and health services data from CancerCare Manitoba (cancer registry and treatment data) The combination of major surgery and perioperative chemoradiation increased from 1% to 25% between 1985 and 1999 Dobie, 2008 (33) United States II–III 1992–1999 2886 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare 45% of patients received both chemotherapy and RT; 38% of stage II and 54% of stage III patients received both chemotherapy and RT Esnaola, 2008 (14) United States I–III 2003–2005 35 695 ≥65, 51 Multiple states; patients identified from the NCDB; health services data obtained by medical record abstraction Increasing age was associated with lower use of chemoradiation Morris, 2008 (34) United States II–III 1992–1999 2716 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Following consultation with an oncologist, 77% of whites and 61% of blacks received both chemotherapy and RT Cronin, 2006 (60) United States II–III 2000 352 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys 55% of stage II and 53% of stage III rectal cancer patients received guideline therapy (surgery + 5-FU + RT) McGory, 2006 (48) United States III 1994–2001 13 231 Mean 69 California; patients identified from the registry; health services data from California Patient Discharge Database 52% of stage I and 62% of stage II patients received chemoradiation Keating, 2005 (52) United States III 1993–1999 48 027 ≥66, 100 Multiple states; patients and health services data identified from SEER–Medicare Increases in market share of managed care by county were associated with receipt of adjuvant chemoradiation for patients with stage II or stage III cancer; rates peaked in areas with a market share of managed care between 1% and 10% (P = 0.001). Dharma- Wardene, 2002 (62) Canada NR 1985–1999 2925 Median 69 Manitoba; patients identified from registry and health services data obtained from CancerCare Manitoba The combination of major surgery and perioperative chemoradiation increased from 1% to 25% between 1985 and 1999 Neugut, 2002 (36) United States II–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 37% of patients received surgery with RT and 5-FU chemotherapy VanEenwyk, 2002 (61) United States III 1996–1997 632 ≥65, 71 Washington; patients identified from the registry linked to hospital discharge data 27% of patients did not receive adjuvant therapy (any chemotherapy or RT); older age and later stage were associated with not having an adjuvant therapy treatment plan Schrag, 2001 (37) United States II–III 1992–1996 1411 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare Overall, 42% of patients received chemoradiation; increasing age reduced likelihood of treatment receipt Shroen, 2001 (21) United States I–IV 1994–1996 637 Range 22–94 California (Sacramento); patients and health services data identified from the Cancer Surveillance Program Evaluated by NIH Consensus Conference recommendations, 44% of stage II patients and 60% of stage III patients received recommended therapy (surgery + RT + chemotherapy) Colorectal White, 2008 (63) United States I–III 1991–2002 55 204 ≥65, 100 Multiple states; patients and health services data identified from SEER–Medicare 77% of white patients and 74% of black patients received standard therapy according to NCI Physician Data Query guidelines Potosky, 2002 (64) United States II–III 1987–1995 4706 ≥20, 100 Multiple states; patients and health services data obtained from SEER registries and supplemental Patterns of Care physician surveys Standard therapy = 5-FU + levamisole/ leucovorin for stage III colon patients, 5-FU with or without RT for stage II/III rectal patients; 78% of patients <55 y received standard therapy; 58% of whites, compared with 47% of blacks, received standard therapy * 5-FU = 5-Fluorouracil; NCDB = National Cancer Data Base; NCI = National Cancer Institute; NIH = National Institutes of Health; NR = not reported; RT = radiotherapy; SEER = Surveillance, Epidemiology, and End Results. † For studies where age distributions were not explicitly stated, we include measures of mean, median, or range as reflected in the original study’s presentation. View Large Postdiagnostic Surveillance Care Patterns of care for the postdiagnostic surveillance of colorectal cancer were reported in 13 studies and were most commonly discussed in the context of achieving various guideline recommendations. Eleven studies were conducted in the United States (52,66–70,74,77–79,81) and two studies were conducted in Canada (65,72). SEER–Medicare data were used to assess postdiagnostic surveillance for a majority of the US studies. Data for the remaining studies in both the United States and Canada were obtained from registry linkages to medical claims, medical record review, or from a national research project designed to survey patterns of care and care outcomes for cancer patients (ie, Cancer Care Outcomes Consortium [CanCORS]). Physical examinations of the bowel or colon (eg, colonoscopy, sigmoidoscopy) accounted for a majority of surveillance methods reported, followed by carcinoembryonic antigen (CEA) testing, physician office visits, and scans of the abdomen, pelvis, or chest. Because various established guidelines were used to evaluate adherence to postdiagnostic surveillance at varying time points following initial treatment, studies reported disparate proportions for receipt of care. In the United States, receipt of surveillance care ranged between 26% and 83% for bowel or colon examinations, and between 60% and 92% for physician office visits. In Canada, 59% to 71% of patients received CEA testing compared with 47% of patients in a US population (65,66). The use of scans for colorectal cancer surveillance has not been included in any published guidelines at the time of this publication; however, US studies reported 7% to 59% for the use of X-ray or positron emission tomographic scans. Receipt of surveillance care was independently associated with race, age, and treatment facility; blacks, older patients, and patients treated in community vs teaching hospitals were less likely to receive care (65,69,77). End-of-Life Care Five studies reported the receipt of end-of-life care for colorectal cancer patients (71,73,75,76,80). These studies were all conducted in the United States and evaluated the use of palliative chemotherapy, hospice care, and hospital or emergency room services. Notably, four of the five studies acquired health services data from Medicare claims. The exception, McCarthy et al. (76), obtained data from a special study seeking to assess patient outcomes (ie, Study to Understand Patient Prognoses and Preferences for Outcomes and Risks of Treatments [SUPPORT]). Discussion In this study, we evaluated contemporary patterns of colorectal cancer care in the United States and Canada, as identified through a systematic review of 73 studies. Although direct comparisons between and within the two countries were limited by differences in study populations and research methods, we generally observed similar patterns of cancer-directed initial care, including rates of surgical treatment, use of adjuvant chemotherapy, and use of radiation therapy in the United States and Canada. Few studies measured postdiagnostic surveillance or end-of-life care. Our findings highlighted research gaps related to treatment practices in the absence of consensus-based guidelines. In addition, the time required to link data sources used to measure patterns of care results in data lags that can affect promising research, as in the case of the SEER–Medicare linkage (83). Researchers, clinicians, and policy makers can use findings from this review in efforts to quantify future economic and health-care resources that will be needed to improve treatment, outcomes, and access to care for colorectal cancer patients treated in the United States and Canada. Findings for cancer-directed surgery in both the United States and Canada showed that most patients were resected, although the specific types of surgery received varied. Since 2000, surgical resection as the sole treatment modality for any colorectal cancer has declined with the addition of neoadjuvant and adjuvant treatment. In recent years, permanent colostomies have occurred less frequently and sphincter-sparing procedures have become a viable option for more rectal cancer patients when radiotherapy is given preoperatively (84). Moreover, the role of radiotherapy among colorectal cancer patients is largely restricted to those with rectal cancer. For these patients, the use of radiotherapy increased over time, whereas rates for colon cancer patients remained stagnant at 20% or less (27,29). This observation is consistent with recommendations for the treatment of colorectal cancer (85), which endorse radiotherapy for patients with rectal cancer, specifically those with stage II or III disease. In contrast, receipt of radiotherapy is only indicated for stage IV colon cancer patients or those who have experienced recurrence. The receipt of neoadjuvant radiotherapy for rectal cancer patients also increased over time (31). Shrinking the tumor preoperatively through neoadjuvant therapy maximizes options for surgical resection and is likely to affect observed patterns of both surgical and adjuvant care. Receipt of chemotherapy increased over time, but varied considerably across studies, ranging between 28% and 90% in the United States and between 0% and 92% in Canada. Chemotherapy receipt was associated with anatomical site of the tumor, stage of disease, and patient insurance status; such wide variation in treatment receipt was due to differences in study populations and research methods. For US and Canadian studies that had comparable patient populations, receipt of chemotherapy was generally similar. Among those receiving chemotherapy, 5-Fluorouracil (5-FU)-based regimens were commonly administered, particularly for patients with stage II–IV colon cancer where such treatment is recommended by guidelines (85). However, with the advent of effective but expensive drugs (86) and use of supportive agents (87), costs associated with chemotherapy are expected to increase over time, potentially introducing an additional barrier for patients to receive appropriate care. Few studies in our review addressed the use of newer chemotherapeutic or biological agents, due, in part, to lags in the availability of data on cancer drugs. Future research should evaluate the specific agents used in colorectal cancer care. Consensus-based guidelines provided the context for many of the studies that assessed multicomponent care in our review; however, guideline adherence varied by study population setting and year of diagnosis, likely because practice guidelines vary in their treatment recommendations. One study assessing treatment in relation to NCCN guidelines among a network of NCCN institutions reported that although guideline adherence varied, the reported receipt of guideline care remained high (>80%), as may be expected among US comprehensive cancer centers (32). In contrast, a population-based study conducted by Shroen et al. demonstrated that only 44% of stage II and 60% of stage III rectal cancer patients obtained recommended therapy, as outlined by the National Institutes of Health Consensus Conference (21). Comparisons of treatment receipt between and within the United States and Canada are limited for early- and late-stage colorectal cancer patients because of the lack of consensus-based guidelines for the two patient groups. Nearly 40% of colorectal cancer patients receive a diagnosis of localized disease, and approximately one-quarter of patients are diagnosed with distant disease. This results in a substantial number of patients whose treatment plans cannot be evaluated in relation to a standard of care (88). Controlled trials for these patient populations will play a large role in guideline development. However, it should be noted that treatment plans vary at the discretion of the treating physician along with patient preferences for care, despite the existence of guideline recommendations. Few studies of postdiagnostic surveillance were identified for our review, and most were conducted in the context of achieving guideline recommendations. Because there was no general consensus on frequency and time to follow-up care across guidelines, proportions of care receipt varied widely. Coordinated development of evidence-based guidelines for postdiagnostic colorectal cancer surveillance is needed to improve patient care, and evaluation of their implementation will be important for future research. Few studies in our literature review addressed end-of-life care for colorectal cancer patients. This is may be expected because end-of-life studies tend to group all cancer patients together and do not report receipt of care separately by cancer site. However, because palliative care is not cancer-directed, this component of end-of-life care may be relatively consistent for all cancer patients. Of the five end-of-life care studies we identified, four were conducted among US patients with Medicare coverage, which promotes the use of hospice care. Future research describing end-of-life care will be important, particularly in Canada, where we did not identify any study and where the availability of hospice care varies by province. A significant proportion of patients did not receive expected surgical or adjuvant care based on tumor site and disease stage, particularly patients who were nonwhite, older age, or who reported comorbidities. In the United States, blacks were least likely to receive any component of colorectal cancer care. However, we identified particularly worrisome findings in our review for chemotherapy use in the context of disparities by race. Although black and white colon cancer patients received consultation with an oncologist in similar proportions, blacks were significantly less likely to receive chemotherapy (34,50). The Canadian studies included in our review generally did not provide data on treatment receipt stratified by race. Studies assessing the association between race and treatment receipt in Canada’s universal health-care system would add to the current body of knowledge regarding disparities in health-care access because barriers to care are assumed to be mitigated in this population. In the United States, more studies of Asian and Hispanic populations, which were underrepresented in our review, are needed to inform efforts that seek to improve care. Older patients and individuals with comorbidities were also consistently less likely to obtain recommended care (36,45,47,61). However, these patient populations typically have contraindications to treatment; thus, data on performance status in future research will allow for improved assessments of patterns of care. Ongoing efforts to improve measurement of comorbidities and to evaluate potential barriers of access to care will inform future efforts to reduce treatment disparities. Though trends in the receipt of care were generally similar between the two countries, we observed differences in the United States and Canada with respect to data resources used to identify colorectal cancer treatment. Health-care payers in each country are central to the availability of patient treatment data. Canada’s universal health coverage provides centralized systems health services data, thereby creating a potential resource that would allow for the continuous observation of patients. However, few provinces or territories have linked registry data to insurance claims. In the United States, varying forms of health-care coverage yield multiple data sources that can be used to measure patterns of care. But the disparate resources pose a challenge in the accurate assessment of care patterns for the US population as a whole. Additionally, measuring patterns of care is limited by discontinuity between data sources and lags in data availability for both countries. In the United States, ongoing state-based efforts to link registry data with multiple health insurance datasets may lead to a more comprehensive view of cancer care patterns (89–91). In Canada, the Canadian Partnership Against Cancer (CPAC) heads several initiatives that seek to improve cancer surveillance, including efforts to reduce information gaps at the national, provincial, and territorial levels (92). In conclusion, this review summarizes a substantial volume of literature on colorectal cancer treatment practices in the United States and Canada, providing a basis for researchers who seek to address research gaps within colorectal cancer populations. Future work in assessing patterns of care for colorectal cancer patients in the United States and Canada should seek to include more studies in the areas of postdiagnostic surveillance and end-of-life care, which were both underrepresented in our review. Although guidelines provide insight on specific aspects of care, ongoing evaluation of the receipt of all types of colorectal cancer care for all stages and tumor sites will be important in identifying over- and underuse of health services. Further, where guideline consensuses do not exist, as in the case of postdiagnostic surveillance care, descriptions of metrics used to assess receipt of care will enable comparisons across studies. Future work should also address challenges to the interpretation of care patterns, including the use of various staging systems, alternating use of clinical or pathological staging, and contraindications to treatment that are not consistently captured or are absent from data sources. High-quality research on patterns of colorectal cancer care will aid policy makers in quantifying the resources needed to treat this population, while addressing disparities, projecting future costs, and ultimately improving care and cancer outcomes. Appendix 1 Search No. Limits: English, Journal Article, Humans, Publication Date from 2000 to 2010 1 “Colorectal Neoplasms/drug therapy”[Mesh] OR “Colorectal Neoplasms/radiotherapy”[Mesh] OR “Colorectal Neoplasms/surgery”[Mesh] OR “Colorectal Neoplasms/therapy”[Mesh] 2 “Physician’s Practice Patterns”[Mesh] 3 “Guideline Adherence”[Mesh] 4 “Health Services/statistics and numerical data”[Majr] OR “Health Services/trends”[Majr] OR “Health Services/utilization”[Majr] 5 “Quality of Health Care/statistics and numerical data”[Majr] OR “Quality of Health Care/trends”[Majr] OR “Quality of Health Care/utilization”[Majr] 6 “Chemotherapy, Adjuvant/statistics and numerical data”[Mesh] OR “Chemotherapy, Adjuvant/trends”[Mesh] OR “Chemotherapy, Adjuvant/utilization”[Mesh] 7 “Neoadjuvant Therapy/statistics and numerical data”[Mesh] OR “Neoadjuvant Therapy/trends”[Mesh] OR “Neoadjuvant Therapy/utilization”[Mesh] 8 “Radiotherapy, Adjuvant/statistics and numerical data”[Mesh] OR “Radiotherapy, Adjuvant/trends”[Mesh] OR “Radiotherapy, Adjuvant/utilization”[Mesh] 9 “Neoplasm Recurrence, Local/prevention and control”[Majr] 10 “Terminal Care”[Mesh] 11 “Patterns of Care”[Keyword String][Abstract or Title] 12 Search No. 1 AND (No. 2 OR No. 3 OR No. 4 OR No. 5 OR No. 6 OR No. 7 OR No. 8 OR No. 9 OR No. 10 OR No. 11) 13 Select studies conducted in the United States or Canada Search No. Limits: English, Journal Article, Humans, Publication Date from 2000 to 2010 1 “Colorectal Neoplasms/drug therapy”[Mesh] OR “Colorectal Neoplasms/radiotherapy”[Mesh] OR “Colorectal Neoplasms/surgery”[Mesh] OR “Colorectal Neoplasms/therapy”[Mesh] 2 “Physician’s Practice Patterns”[Mesh] 3 “Guideline Adherence”[Mesh] 4 “Health Services/statistics and numerical data”[Majr] OR “Health Services/trends”[Majr] OR “Health Services/utilization”[Majr] 5 “Quality of Health Care/statistics and numerical data”[Majr] OR “Quality of Health Care/trends”[Majr] OR “Quality of Health Care/utilization”[Majr] 6 “Chemotherapy, Adjuvant/statistics and numerical data”[Mesh] OR “Chemotherapy, Adjuvant/trends”[Mesh] OR “Chemotherapy, Adjuvant/utilization”[Mesh] 7 “Neoadjuvant Therapy/statistics and numerical data”[Mesh] OR “Neoadjuvant Therapy/trends”[Mesh] OR “Neoadjuvant Therapy/utilization”[Mesh] 8 “Radiotherapy, Adjuvant/statistics and numerical data”[Mesh] OR “Radiotherapy, Adjuvant/trends”[Mesh] OR “Radiotherapy, Adjuvant/utilization”[Mesh] 9 “Neoplasm Recurrence, Local/prevention and control”[Majr] 10 “Terminal Care”[Mesh] 11 “Patterns of Care”[Keyword String][Abstract or Title] 12 Search No. 1 AND (No. 2 OR No. 3 OR No. 4 OR No. 5 OR No. 6 OR No. 7 OR No. 8 OR No. 9 OR No. 10 OR No. 11) 13 Select studies conducted in the United States or Canada View Large References 1. Ferlay J Shin HR Bray F Forman D Mathers C Parkin DM . GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 . Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr. Accessed June 7, 2013. 2. Siegel R Naishadham D Jemal A . Cancer statistics, 2012 [published online ahead of print January 13, 2012]. CA Cancer J Clin . 2012; 62( 1): 10– 29. doi: 10.3322/caac.20138. 3. Canadian Cancer Society’s Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011 . Toronto, ON: Canadian Cancer Society; 2011. Google Scholar 4. Edwards BK Ward E Kohler BA et al. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates [published online ahead of print December 10, 2009]. Cancer . 2010; 116( 3): 544– 573. doi: 10.1002/cncr.24760. 5. Phillips KA Liang SY Ladabaum U et al. Trends in colonoscopy for colorectal cancer screening. [published online ahead of print January 17, 2007]. Med Care . 2007; 45( 2): 160– 167. doi: 10.1002/cncr.24760. 6. Hurwitz H Fehrenbacher L Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. [published online ahead of print June 4, 2004]. N Engl J Med . 2004; 350( 23): 2335– 2342. doi: 10.1056/NEJMoa032691. 7. Schrag D . The price tag on progress—chemotherapy for colorectal cancer. [published online ahead of print July 23, 2004]. N Engl J Med . 2004; 351( 4): 317– 319. doi: 0.1056/NEJMp048143. 8. Chawla N Butler EN Lund J Warren JL Harlan LC Yabroff KR . Patterns of care in Europe, Australia, and New Zealand. J Natl Cancer Inst Monogr . 2013; 46( 1): 36– 61. 9. Hardiman KM Cone M Sheppard BC Herzig DO . Disparities in the treatment of colon cancer in octogenarians. [published online ahead of print April 28, 2009]. Am J Surg . 2009; 197( 5): 624– 628. doi: 10.1016/j.amjsurg.2008.12.018. 10. Pisu M Richardson LC Kim YI et al. Less-than-standard treatment in rectal cancer patients: which patients are at risk [published online ahead of print April 2, 2010]? J Natl Med Assoc . 2010; 102( 3): 190– 198. 11. Ricciardi R Roberts PL Read TE Marcello PW Schoetz DJ Baxter NN . Variability in reconstructive procedures following rectal cancer surgery in the United States. [published online ahead of print May 21, 2010]. Dis Colon Rectum . 2010; 53( 6): 874– 880. doi: 10.1007/DCR.0b013e3181cf6f58. 12. Latosinsky S Turner D . Local recurrence after rectal cancer treatment in Manitoba. [published online ahead of print February 2, 2009]. Can J Surg . 2009; 52( 1): 45– 50. 13. Demers AA Latosinsky S Turner D . Survival and treatment trends of rectal cancer patients in a population with suboptimal local control. [published online ahead of print November 6, 2007]. Eur J Surg Oncol . 2008; 34( 6): 655– 661. doi: 10.1016/j.ejso.2007.09.002. 14. Esnaola NF Stewart AK Feig BW Skibber JM Rodriguez-Bigas MA . Age-, race-, and ethnicity-related differences in the treatment of nonmetastatic rectal cancer: a patterns of care study from the national cancer data base. [published online ahead of print August 21, 2008]. Ann Surg Oncol . 2008; 15( 11): 3036– 3047. doi: 10.1245/s10434-008-0106-9. 15. Chang GJ Skibber JM Feig BW Rodriguez-Bigas M . Are we undertreating rectal cancer in the elderly? An epidemiologic study. [published online ahead of print August 2, 2007]. Ann Surg . 2007; 246( 2): 215– 221. doi: 10.1097/SLA.0b013e318070838f. 16. Ricciardi R Virnig BA Madoff RD Rothenberger DA Baxter NN . The status of radical proctectomy and sphincter-sparing surgery in the United States. [published online ahead of print June 19, 2007]. Dis Colon Rectum . 2007; 50( 8): 1119– 1127; discussion 1126–1127. doi: 10.1007/s10350-007-0250-5. 17. Morris AM Wei Y Birkmeyer NJ Birkmeyer JD . Racial disparities in late survival after rectal cancer surgery. [published online ahead of print November 25, 2006]. J Am Coll Surg . 2006; 203( 6): 787– 794. doi: 10.1016/j.jamcollsurg.2006.08.005. 18. Purves H Pietrobon R Hervey S Guller U Miller W Ludwig K . Relationship between surgeon caseload and sphincter preservation in patients with rectal cancer. [published online ahead of print April 7, 2005]. Dis Colon Rectum . 2005; 48( 2): 195– 202; discussion 202–204. doi: 10.1007/s10350-004-0793-7. 19. Morris AM Billingsley KG Baxter NN Baldwin LM . Racial disparities in rectal cancer treatment: a population-based analysis. [published online ahead of print February 11, 2004]. Arch Surg . 2004; 139( 2): 151– 155; discussion 6. doi: 10.1001/archsurg.139.2.151. 20. Phang PT MacFarlane JK Taylor RH et al. Practice patterns and appropriateness of rectal cancer management in British Columbia. BC Med J . 2003; 45( 7): 324– 329. 21. Schroen AT Cress RD . Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. [published online ahead of print October 31, 2001]. Ann Surg . 2001; 234( 5): 641– 651. 22. Chan TW Brown C Ho CC Gill S . Primary tumor resection in patients presenting with metastatic colorectal cancer: analysis of a provincial population-based cohort. [published online ahead of print August 26, 2009]. Am J Clin Oncol . 2010; 33( 1): 52– 55. doi: 10.1097/COC.0b013e31819e902d. 23. Diggs JC Xu F Diaz M Cooper GS Koroukian SM . Failure to screen: predictors and burden of emergency colorectal cancer resection. [published online ahead of print March 6, 2007]. Am J Manag Care . 2007; 13( 3): 157– 164. 24. Cook AD Single R McCahill LE . Surgical resection of primary tumors in patients who present with stage IV colorectal cancer: an analysis of surveillance, epidemiology, and end results data, 1988 to 2000. [published online ahead of print June 21, 2005]. Ann Surg Oncol . 2005; 12( 8): 637– 345. doi: 10.1245/ASO.2005.06.012. 25. Temple LK Hsieh L Wong WD Saltz L Schrag D . Use of surgery among elderly patients with stage IV colorectal cancer. [published online ahead of print September 1, 2004]. J Clin Oncol . 2004; 22( 17): 3475– 3484. doi: 10.1200/JCO.2004.10.218. 26. Wudel LJ Jr Chapman WC Shyr Y et al. Disparate outcomes in patients with colorectal cancer: effect of race on long-term survival. [published online ahead of print May 2, 2002]. Arch Surg . 2002; 137( 5): 550– 554; discussion 554–556. 27. Roetzheim RG Pal N Gonzalez EC Ferrante JM Van Durme DJ Krischer JP . Effects of health insurance and race on colorectal cancer treatments and outcomes. [published online ahead of print November 15, 2000]. Am J Public Health . 2000; 90( 11): 1746– 1754. 28. Simunovic M To T Baxter N et al. Hospital procedure volume and teaching status do not influence treatment and outcome measures of rectal cancer surgery in a large general population. [published online ahead of print April 18, 2000]. J Gastrointest Surg . 2000; 4( 3): 324– 330. 29. Dunn EF Kozak KR Moody JS . External beam radiotherapy for colon cancer: patterns of care. [published online ahead of print July 22, 2009]. Int J Radiat Oncol Biol Phys . 2010; 76( 5): 1420– 1424. doi: 10.1016/j.ijrobp.2009.03.014. 30. Kuo I Wong JH Roy-Chowdhury S Lum SS Morgan JW Kazanjian K . The use of pelvic radiation in stage II rectal cancer: a population-based analysis. [published online ahead of print October 26, 2010]. Am Surg . 2010; 76( 10): 1092– 1095. 31. Lin C Charlton ME Meza JL Enke CA Loberiza FR Jr Temporal and regional variations in the use of preoperative radiation therapy for rectal cancer. [published online ahead of print December 3, 2009]. Am J Clin Oncol . 2010; 33( 5): 443– 447. doi: 10.1097/COC.0b013e3181b4b175. 32. Romanus D Weiser MR Skibber JM et al. Concordance with NCCN Colorectal Cancer Guidelines and ASCO/NCCN Quality Measures: an NCCN institutional analysis. [published online ahead of print September 17, 2009]. J Natl Compr Canc Netw . 2009; 7( 8): 895– 904. 33. Dobie SA Warren JL Matthews B Schwartz D Baldwin LM Billingsley K . Survival benefits and trends in use of adjuvant therapy among elderly stage II and III rectal cancer patients in the general population. [published online ahead of print January 15, 2008]. Cancer . 2008; 112( 4): 789– 799. doi: 10.1002/cncr.23244. 34. Morris AM Billingsley KG Hayanga AJ Matthews B Baldwin LM Birkmeyer JD . Residual treatment disparities after oncology referral for rectal cancer. [published online ahead of print May 15, 2008]. J Natl Cancer Inst . 2008; 100( 10): 738– 744. doi: 10.1093/jnci/djn145. 35. Baxter NN Rothenberger DA Morris AM Bullard KM . Adjuvant radiation for rectal cancer: do we measure up to the standard of care? An epidemiologic analysis of trends over 25 years in the United States. [published online ahead of print February 5, 2005]. Dis Colon Rectum . 2005; 48( 1): 9– 15. doi: 10.1007/s10350-004-0792-8. 36. Neugut AI Fleischauer AT Sundararajan V et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. [published online ahead of print June 1, 2002]. J Clin Oncol . 2002; 20( 11): 2643– 2650. 37. Schrag D Gelfand SE Bach PB Guillem J Minsky BD Begg CB . Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. [published online ahead of print September 5, 2001]. J Clin Oncol . 2001; 19( 17): 3712– 3718. 38. Ayanian JZ Zaslavsky AM Fuchs CS et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. [published online ahead of print March 29, 2003]. J Clin Oncol . 2003; 21( 7): 1293– 1300. doi: 10.1200/JCO.2003.06.178. 39. Kirkpatrick HM Aitelli CL Qin H Becerra C Lichliter WE McCollum AD . Referral patterns and adjuvant chemotherapy use in patients with stage II colon cancer. [published online ahead of print July 21, 2010]. Clin Colorectal Cancer . 2010; 9( 3): 150– 156. doi: 10.3816/CCC.2010.n.020. 40. Winget M Hossain S Yasui Y Scarfe A . Characteristics of patients with stage III colon adenocarcinoma who fail to receive guideline-recommended treatment. [published online ahead of print June 26, 2010]. Cancer . 2010; 116( 20): 4849– 4856. doi: 10.1002/cncr.25250. 41. Earle CC Weiser MR Ter Veer A et al. Effect of lymph node retrieval rates on the utilization of adjuvant chemotherapy in stage II colon cancer. [published online ahead of print August 22, 2009]. J Surg Oncol . 2009; 100( 7): 525– 528. doi: 10.1002/jso.21373. 42. Hershman DL Buono DL Malin J McBride R Tsai WY Neugut AI . Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. [published online ahead of print November 12, 2009]. J Natl Cancer Inst . 2009; 101( 23): 1633– 41. doi: 10.1093/jnci/djp387. 43. Wirtzfeld DA Mikula L Gryfe R et al. Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. [published online ahead of print April 29, 2009]. Can J Surg . 2009; 52( 2): 92– 97. 44. Bradley CJ Given CW Dahman B Fitzgerald TL . Adjuvant chemotherapy after resection in elderly Medicare and Medicaid patients with colon cancer. [published online ahead of print March 12, 2008]. Arch Intern Med . 2008; 168( 5): 521– 529. doi: 10.1001/archinternmed.2007.82. 45. Quah HM Joseph R Schrag D et al. Young age influences treatment but not outcome of colon cancer. [published online ahead of print June 27, 2007]. Ann Surg Oncol . 2007; 14( 10): 2759– 2765. doi: 10.1245/s10434-007-9465-x. 46. Dobie SA Baldwin LM Dominitz JA Matthews B Billingsley K Barlow W . Completion of therapy by Medicare patients with stage III colon cancer. [published online ahead of print May 4, 2006]. J Natl Cancer Inst . 2006; 98( 9): 610– 619. doi: 10.1093/jnci/djj159. 47. Luo R Giordano SH Freeman JL Zhang D Goodwin JS . Referral to medical oncology: a crucial step in the treatment of older patients with stage III colon cancer. [published online ahead of print October 13, 2006]. Oncologist . 2006; 11( 9): 1025– 1033. doi: 10.1634/theoncologist.11-9-1025. 48. McGory ML Zingmond DS Sekeris E Bastani R Ko CY . A patient’s race/ethnicity does not explain the underuse of appropriate adjuvant therapy in colorectal cancer. [published online ahead of print February 14, 2006]. Dis Colon Rectum . 2006; 49( 3): 319– 329. doi: 10.1007/s10350-005-0283-6. 49. Neugut AI Matasar M Wang X et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. [published online ahead of print April 19, 2006]. J Clin Oncol . 2006; 24( 15): 2368– 2375. doi: 10.1200/JCO.2005.04.5005. 50. Baldwin LM Dobie SA Billingsley K et al. Explaining black-white differences in receipt of recommended colon cancer treatment. [published online ahead of print August 18, 2005]. J Natl Cancer Inst . 2005; 97( 16): 1211– 1220. doi: 10.1093/jnci/dji241. 51. Jessup JM Stewart A Greene FL Minsky BD . Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. [published online ahead of print December 8, 2005]. J Natl Med Assoc . 2005; 294( 21): 2703– 2711. doi: 10.1001/jama.294.21.2703. 52. Keating NL Landrum MB Meara E Ganz PA Guadagnoli E . Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector? [published online ahead of print February 17, 2005]. J Natl Cancer Inst . 2005; 97( 4): 257– 264. doi: 10.1093/jnci/dji044. 53. Wu X Chen VW Andrews PA Chen L Hsieh M Fontham ET . Treatment patterns for stage III colon cancer and factors related to receipt of postoperative chemotherapy in Louisiana. [published online ahead of print November 24, 2004]. J La State Med Soc . 2004; 156( 5): 255– 261. 54. Sundararajan V Mitra N Jacobson JS Grann VR Heitjan DF Neugut AI . Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. [published online ahead of print March 5, 2002]. Ann Intern Med . 2002; 136( 5): 349– 357. 55. Schrag D Cramer LD Bach PB Begg CB . Age and adjuvant chemotherapy use after surgery for stage III colon cancer. [published online ahead of print June 8, 2001]. J Natl Cancer Inst . 2001; 93( 11): 850– 857. 56. Sundararajan V Grann VR Jacobson JS Ahsan H Neugut AI . Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. [published online ahead of print June 23, 2001]. Cancer . 2001; 7( 3): 213– 218. 57. Hendren S Birkmeyer JD Yin H Banerjee M Sonnenday C Morris AM . Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. [published online ahead of print December 24, 2010]. Dis Colon Rectum . 2010; 53( 12): 1587– 1593. doi: 10.1007/DCR.0b013e3181f2f202. 58. Oliveria SA Yood MU Campbell UB Yood SM Stang P . Treatment and referral patterns for colorectal cancer. [published online ahead of print August 21, 2004]. Med Care . 2004; 42( 9): 901– 906. 59. Cree M Tonita J Turner D et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan, and Manitoba in 2004. [published online ahead of print July 28, 2009]. Clin Colorectal Cancer . 2009; 8( 3): 141– 145. doi: 10.3816/CCC.2009.n.023. 60. Cronin DP Harlan LC Potosky AL Clegg LX Stevens JL Mooney MM . Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. [published online ahead of print October 13, 2006]. Am J Gastroenterol . 2006; 101( 10): 2308– 2318. doi: 10.1111/j.1572-0241.2006.00775.x. 61. VanEenwyk J Campo JS Ossiander EM . Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. [published online ahead of print July 13, 2002]. Cancer . 2002; 95( 1): 39– 46. doi: 10.1002/cncr.10645. 62. Dharma-Wardene MW de Gara C Au HJ Hanson J Hatcher J . Ageism in rectal carcinoma? Treatment and outcome variations. [published online ahead of print June 10, 2003]. Int J Gastrointest Cancer . 2002; 32( 2–3): 129– 138. doi: 10.1385/IJGC:32:2–3:129. 63. White A Liu CC Xia R et al. Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002. [published online ahead of print October 22, 2008]. Cancer . 2008; 113( 12): 3400– 3409. doi: 10.1002/cncr.23924. 64. Potosky AL Harlan LC Kaplan RS Johnson KA Lynch CF . Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. [published online ahead of print March 1, 2002]. J Clin Oncol . 2002; 20( 5): 1192– 1202. 65. Cheung WY Pond GR Rother M et al. Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancer. [published online ahead of print July 16, 2008]. Clin Colorectal Cancer . 2008; 7( 3): 191– 196. doi: 10.3816/CCC.2008.n.025. 66. Cooper GS Kou TD Reynolds HL Jr Receipt of guideline-recommended follow-up in older colorectal cancer survivors: a population-based analysis. [published online ahead of print September 10, 2008]. Cancer . 2008; 113( 8): 2029– 2037. doi: 10.1002/cncr.23823. 67. Cooper GS Payes JD . Temporal trends in colorectal procedure use after colorectal cancer resection. [published online ahead of print December 5, 2006]. Gastrointest Endosc . 2006; 64( 6): 933– 940. doi: 10.1016/j.gie.2006.08.024. 68. Cooper GS Yuan Z Chak A Rimm AA . Patterns of endoscopic follow-up after surgery for nonmetastatic colorectal cancer. [published online ahead of print July 7, 2007]. Gastrointest Endosc . 2000; 52( 1): 33– 38. doi: 10.1067/mge.2000.106685. 69. Ellison GL Warren JL Knopf KB Brown ML . Racial differences in the receipt of bowel surveillance following potentially curative colorectal cancer surgery. [published online ahead of print January 1, 2004]. Health Serv Res . 2003; 38( 6 pt 2): 1885– 1903. doi: 10.1111/j.1475-6773.2003.00207.x. 70. Elston Lafata J Cole Johnson C Ben-Menachem T Morlock RJ . Sociodemographic differences in the receipt of colorectal cancer surveillance care following treatment with curative intent. [published online ahead of print May 1, 2001]. Med Care . 2001; 39( 4): 361– 372. 71. Emanuel EJ Young-Xu Y Levinsky NG Gazelle G Saynina O Ash AS . Chemotherapy use among Medicare beneficiaries at the end of life. [published online ahead of print April 16, 2003]. Ann Intern Med . 2003; 138( 8): 639– 643. 72. Hilsden RJ Bryant HE Sutherland LR Brasher PM Fields AL . A retrospective study on the use of post-operative colonoscopy following potentially curative surgery for colorectal cancer in a Canadian province. [published online ahead of print April 21, 2004]. BMC Cancer . 2004; 4 14. doi: 10.1186/1471-2407-4-14. 73. Keating NL Landrum MB Lamont EB Earle CC Bozeman SR McNeil BJ . End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector. [published online ahead of print June 22, 2009]. Cancer . 2010; 116( 15): 3732– 3739. doi: 10.1002/cncr.25077. 74. Knopf KB Warren JL Feuer EJ Brown ML . Bowel surveillance patterns after a diagnosis of colorectal cancer in Medicare beneficiaries. [published online ahead of print October 26, 2001]. Gastrointest Endosc . 2001; 54( 5): 563– 571. 75. Lang K Lines LM Lee DW Korn JR Earle CC Menzin J . Trends in healthcare utilization among older Americans with colorectal cancer: a retrospective database analysis. [published online ahead of print December 17, 2009]. BMC Health Serv Res . 2009; 9: 227. doi: 10.1186/1472-6963-9-227. 76. McCarthy EP Phillips RS Zhong Z Drews RE Lynn J . Dying with cancer: patients’ function, symptoms, and care preferences as death approaches. [published online ahead of print May 16, 2000]. J Am Geriatr Soc . 2000; 48( 5 suppl): S110– S121. 77. Rolnick S Hensley Alford S Kucera GP et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. [published online ahead of print November 17, 2005]. J Natl Cancer Inst Monogr 2005;( 35): 96– 101. doi: 10.1093/jncimonographs/lgi045. 78. Rulyak SJ Mandelson MT Brentnall TA Rutter CM Wagner EH . Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer. [published online ahead of print January 28, 2004]. Gastrointest Endosc . 2004; 59( 2): 239– 247. 79. Salz T Weinberger M Ayanian JZ et al. Variation in use of surveillance colonoscopy among colorectal cancer survivors in the United States. [published online ahead of print September 3, 2010]. BMC Health Serv Res . 2010; 10: 256. doi: 10.1186/1472-6963-10-256. 80. Shugarman LR Bird CE Schuster CR Lynn J . Age and gender differences in Medicare expenditures at the end of life for colorectal cancer decedents. [published online ahead of print March 29, 2007]. J Womens Health (Larchmt) . 2007; 16( 2): 214– 227. doi: 10.1089/jwh.2006.0012. 81. Snyder CF Earle CC Herbert RJ Neville BA Blackford AL Frick KD . Trends in follow-up and preventive care for colorectal cancer survivors. [published online ahead of print January 17, 2008]. J Gen Intern Med . 2008; 23( 3): 254– 259. doi: 10.1007/s11606-007-0497-5. 82. Colorectal Cancer Collaborative Group. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. [published online ahead of print October 31, 2001]. Lancet . 2001; 358( 9290): 1291– 1304. doi: 10.1016/S0140-6736(01)06409-1. Google Scholar 83. Warren JL Klabunde CN Schrag D Bach PB Riley GF . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. [published online ahead of print August 21, 2002]. Med Care . 2002; 40( 8 suppl): 3– 18, iv. doi: 10.1097/01.MLR.0000020942.47004.03. 84. Wagman R Minsky BD Cohen AM Guillem JG Paty PP . Sphincter preservation in rectal cancer with preoperative radiation therapy and coloanal anastomosis: long term follow-up. [published online ahead of print September 25, 1998]. Int J Radiat Oncol Biol Phys . 1998; 42( 1): 51– 57. 85. National Institutes of Health Adjuvant therapy for patients with colon and rectal cancer. [published online ahead of print September 19, 1990]. J Natl Med Assoc . 1990; 264( 11): 1444– 1450. Google Scholar 86. Elkin EB Bach PB . Cancer’s next frontier: addressing high and increasing costs. [published online ahead of print March 18, 2010]. J Natl Med Assoc . 2010; 303( 11): 1086– 1087. doi: 10.1001/jama.2010.283. 87. Du XL Lairson DR Begley CE Fang S . Temporal and geographic variation in the use of hematopoietic growth factors in older women receiving breast cancer chemotherapy: findings from a large population-based cohort. [published online ahead of print November 30, 2005]. J Clin Oncol . 2005; 23( 34): 8620– 8628. doi: 10.1200/JCO.2005.02.6252. 88. Howlader NA Krapcho M Neyman N et al. , eds. SEER Cancer Statistics Review, 1975–2008 . Bethesda, MD: National Cancer Institute; 2011. http://seer.cancer.gov/csr/1975_2008. 89. Boscoe FP Schrag D Chen K Roohan PJ Schymura MJ . Building capacity to assess cancer care in the Medicaid population in New York State. [published ahead of print December 17, 2010]. Health Serv Res . 2011; 46( 3): 805– 820. doi: 10.1111/j.1475-6773.2010.01221.x. 90. Bradley CJ Given CW Luo Z Roberts C Copeland G Virnig BA . Medicaid, Medicare, and the Michigan Tumor Registry: a linkage strategy. [published online ahead of print July 21, 2007]. Med Decis Making . 2007; 27( 4): 352– 363. doi: 10.1177/0272989X07302129. 91. Lipscomb J Gillespie TW . State-level cancer quality assessment and research: building and sustaining the data infrastructure. [published online ahead of print July 30, 2007]. Cancer . 2011; 17( 4): 246– 256. doi: 10.1097/PPO.0b013e3182296422. 92. Canadian Partnership Against Cancer Web site. http://www.partnershipagainstcancer.ca/. Accessed June 7, 2013. Google Scholar © The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
JNCI Monographs – Oxford University Press
Published: Aug 16, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.